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Abstract 
My graduate research focuses on engineering and characterizing gramicidin A (gA), a 
natural fifteen-residue transmembrane channel peptide. It consists of D- and L- amino acids at 
alternate positions. gA is believed to fold into a -helix in membranes, and two folded monomers 
at each leaflet of the lipid bilayer dimerize to form a transmembrane channel.  gA shares the 
common features of other known membrane channels: a well defined structure that only allows 
the passage of specific ions, a gating mechanism, and a high abundance of aromatic residues. This 
dissertation includes two subprojects: 
I. Understanding Channel Formation: Aromatic Modifications of Gramicidin A Channel 
Ion channels are key elements in signaling and molecule transport, and therefore crucial 
for normal function of cells. Defective ion channels are known to be responsible for a number of 
diseases. Although hundreds of crystallographic structures of membrane proteins have been 
deposited into the PDB in the past few decades, our knowledge on this large family of proteins is 
still limited and mostly descriptive. Study of small peptides in model membranes is a good 
simplification of the more complex biological systems. In chapter 1, I will introduce my research 
using gA as a model system to understand the significant role of aromatic residues in membrane 
channel structure formation. Channel activities of these gA-Ar mutants were evaluated by ion 
leakage assays. The structure activity relationship of a library of gA mutants was discussed. The 
alternating chirality of amino acids was proven to be essential for gA channel activity. Several 
additional  interesting observations are discussed.  
 
II. Towards Bacterium Specific Ion Channels: Solublized Gramicidin A as Potential 
Systemic Antibiotics  
 
The rapid development of multidrug resistance by pathogenic bacteria poses a serious 
threat to society and demands new antibiotics with different mechanisms. Often considered as a 
model transmembrane channel, gA also has proven antibiotic activities. The gA channel 
facilitates passive diffusion of water and monovalent cations (e.g. H+, Na+, K+) thus killing 
bacteria by disrupting the ion gradient across the cell membrane.  However because of its poor 
solubility and high toxicity, its medicinal application as an antibiotic has been limited to topical 
reagents. A detailed understanding of gA allows rational optimization of the gA-WT to potential 
systemic antibiotics.  
Bacterial membranes are composed of a large fraction of anionic species, therefore, we 
hypothesize that strategic incorporation of cationic residues into gA will afford bacterium-
specific toxicities. In addition, the charged residues will greatly improve the water solubility of 
gA. In chapter 2, I will introduce my research on developing soluble and bacterium specific gA 
as a potential systemic antibiotic. We firstly incorporated D-Lys at the C-terminus to obtain our 
first generation of gA based antibiotics. The best candidate (D-Leu10,12,14D-Lys gA) shows 
significantly increased water solubility (~ 1, 000 times) and therapeutic index (> 50 times). 
Modifications on the Lys side chain were then carried out to fine tune the antibiotic activities of 
these cationic gA. My research has pointed out a possible strategy to convert hydrophobic 
membrane channel peptides into potential systemic antibiotics.  
In addition to targeting the negative charges of bacterial membranes with cationic gA 
mutants, we proposed a novel strategy in which boronic acid is used to chase after the 1,2-diol 
substructure in the PG headgroup through boronate ester formation.  Polyvalent display of 
boronic acids on a peptide scaffold results in enhanced binding with diols, showing promise of 
the boronate approach in the development of bacterium specific reagents. 
 
i 
 
Acknowledgements 
 
First of all I would like to especially thank my advisor Prof. Jianmin Gao for his 
education, support, and help during my Ph.D. studies. He has been always encouraging and 
supportive, giving me confidence and has inspired me in the research. I am so lucky to have him 
as my advisor. His great personality and habits as a scientist will influence me for the rest of my 
life. 
I would like to thank the members of my thesis defense committee: Prof. Mary Roberts, 
Prof. Eranthie Weerapana, and Prof. Kian Tan for taking time to critically read my thesis and to 
attend my defense. I would like to thank Prof. Jianmin Gao again for his help in finishing my 
thesis. 
I would like to thank Christopher Pace for carefully reviewing my thesis and for the great 
collaboration experience; Prof. Eranthie Weerapana for teaching me handling cells; Dr. Luoheng 
Qin for the help in organic synthesis; Yue for making the azatryptophan; Patrick Wong for his 
help in several subprojects. These nice and smart people helped me a lot in my graduate studies.  
I would like to thank my parents for everything they have done for me, for their love and 
care during my whole life. I would to thank my husband for his love and support; my friends for 
their friendship. 
Finally, I would like to thank all the current and past group members of the Gao lab. I 
have enjoyed graduate study largely because of these people around me. 
 
 
 
 
ii 
 
Table of Contents 
Chapter 1. Understanding Channel Formation: Aromatic Modification of Gramicidin A 
Channel ........................................................................................................................................... 1 
1.1 Introduction ............................................................................................................................ 1 
1.1.1 Membrane channels  ........................................................................................................ 1 
1.1.2 Aromatic residues in membrane proteins  ....................................................................... 2 
1.1.3 Gramicidin A channel  .................................................................................................... 3 
1.1.4 Membrane channel characterization  ............................................................................... 7 
1.2 Synthesis and characterization of aromatic mutations of gA channel  ................................. 10 
1.2.1 Selection of aromatic residues and peptide synthesis  ................................................... 10 
1.2.2 Characterization of gA mutants with aromatic modifications  ...................................... 13 
1.3 Summary  ............................................................................................................................. 27 
1.4 Materials and methods  ......................................................................................................... 29 
      References   .......................................................................................................................... 41 
Chapter 2. Towards Bacterium Specific Ion Channels: Solublized Gramicidin A as 
Potential Systemic Antibiotics  .................................................................................................... 45 
2.1 Introduction  ......................................................................................................................... 45 
2.1.1 Antibiotic resistance  ..................................................................................................... 45 
2.1.2 Antimicrobial peptides  ................................................................................................. 47 
2.1.3 Gramicidin A as an antibiotic   ...................................................................................... 49 
2.2 Design and characterization of solubilized gA   ................................................................... 50 
iii 
 
2.2.1 Synthesis and structure analysis of the gA mutants   .................................................... 51 
2.2.2 In vitro characterization of solubilized gA  ................................................................... 52 
2.2.3 Cell based  antimicrobial activity and toxicity evaluation  ........................................... 58 
2.2.4 Summary   ..................................................................................................................... 62 
2.3 Lys side chain modifications of the solubilized gA   ............................................................ 64 
2.3.1 Hydrophobicity and antimicrobial peptides    ............................................................... 64 
2.3.2 Synthesis and characterization of gA mutants with Lys N- trimethylation   ................ 65 
2.3.3 Synthesis and characterization of gA mutants with Lys N-dimethylation and D-Lys 
homologs  ............................................................................................................................... 77 
2.3.4 Summary   ..................................................................................................................... 80 
2.4 Using boronic acid to target bacterial membranes   ............................................................. 81 
2.4.1 Targeting PG headgroup with boronic acid   ................................................................. 81 
2.4.2 Detection of boronic acid and 1,2-diol binding   ........................................................... 81 
2.4.3 Summary   ..................................................................................................................... 92 
2.5 Materials and methods   ........................................................................................................ 93 
      References   ........................................................................................................................ 108 
 
 
 
 
 
iv 
 
List of Abbreviations: 
7-AW L-7-azatryptophan  
AES Atomic emission spectroscopy 
AMPs Antimicrobial peptides 
Ar Aromatic amino acids 
Arg, R Arginine 
ARS Alizarin Red S  
AW 7-azatryptophan 
B. subtilis Bacillus. Subtilis 
Boc tert-Butoxycarbonyl 
Bpa, B Boronophenylalanine 
BSA Bovine serum albumin  
CD Circular dichroism spectra 
CL Cardiolipin 
Dab 2,4-Diaminobutyric acid 
Dap 2,3-Diaminopropionic acid 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
DIC N,N′-Diisopropylcarbodiimide 
DIPEA Diisopropylethylamine 
DLS Dynamic light scattering 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
v 
 
DPA Dipicolinic acid 
DPC Fos-Choline-12 
dppf 1,1'-Bis(diphenylphosphino)ferrocene 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ESI Electrospray ionization 
EYPC Egg yolk phosphatidylcholine  
f4Y tetraflurophenylalanine 
FBS Fetal bovine serum 
Fmoc Fluorenylmethyloxycarbonyl 
Fmoc-Cl Fluorenylmethyloxycarbonyl chloride 
Fmoc-OSU  N-(9-Fluorenylmethoxycarbonyloxy) succinimide 
gA Gramicidin A 
Gly, G Glycine 
HATU 
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HBTU O-BenzotriazoleN,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HC50 50% hemoglobin release from human red blood cells concentration 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HOAt 1-Hydroxy-7-azabenzotriazole 
HOBt Hydroxybenzotriazole 
HPTS 8-hydroxy-1, 3, 6-pyrenetrisulfonate  
hRBCs human red blood cells   
KC50 Half potassium release from human red blood cells 
vi 
 
Kd Dissociation constant 
K-ISE Potassium ion selective electrode 
L/P ratio lipid/peptides ratio 
LC50 50% leakage concentration 
LC-MS Liquid chromatography – mass spectrometry 
Leu. L Leucine 
LP3B lipid binding peptide with 3 PBA 
LUVs Large unilamellar vesicles 
Lys, K Lysine 
MeOH Methanol 
MIC Minimum inhibitory concentration 
MOPS 3-(N-morpholino)propanesulfonic acid 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NMR Nuclear magnetic resonance 
OD Optical density 
Orn Ornithine 
Pal Pyridyl alanine 
PBA Phenylboronic acid 
PBS Phosphate buffer solution 
PC Phosphatidylcholine 
PDB Protein data bank 
PE Phosphatidylethanolamine  
pen Pencillin 
PESF Phenylmethylsulfonyl fluoride 
vii 
 
PG Phosphatidylglycerol  
Phe, F Phenylalanine 
pin Pinacol 
PLP Pyridoxal 5'-phosphate 
POPC 1-Palmitoyl-2-oleoylphosphatidylcholine 
POPG 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 
RP-HPLC Reverse phase – high pressure liquid chromatography 
RT Room temperature 
S. aureus Staphylococcus aureus 
S. pyogenes Streptococcus pyogenes  
SAR structure activity relationship 
SBFI Sodium-binding benzofuran isophthalate 
SDS Sodium dodecyl sulfate 
SEC-HPLC Size exclusion high performance liquid chromatography  
SM Sphingomyelin 
SPPS Solid phase peptide synthesis  
strep Streptomycin 
SUVs Small unilamellar vesicles  
TES 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
Trp Trptophan 
Tyr, Y Tyrosine 
viii 
 
UV Ultra violet 
Vis Visible light  
 Encapsulating 
 
ix 
 
List of Tables: 
Table 1-1. Structures and important properties of the aromatic residues used in modification  .... 11 
Table 1-2. The retention times of gA mutants off the SEC-HPLC ................................................ 15 
Table 1-3. Sequences and MS of the gA-Ar mutants discussed in chapter 1  ............................... 34 
Table 2-1. Modes of action and resistance mechanisms of commonly used antibiotics  ............... 46 
Table 2-2.  Sequences of the gA mutants discussed in section 2.2  ............................................... 52 
Table 2-3. Antibacterial activity and preliminary toxicity against hRBCS of gA mutants  .......... 60 
Table 2-4. Sequences and Lys N-trimethylated gA mutants  ....................................................... 65 
Table 2-5. Hydrophobicity and solubility comparison of gA mutants .......................................... 66 
Table 2-6. Antimicrobial activities and toxicity against hRBCs of gA-xM mutants  .................... 68 
Table 2-7. Therapeutic indices comparison of gA-x and gA-xM mutants  ................................... 70 
Table 2-8.  Dissociation constant (Kd) of gA-x and gA-xM mutants ............................................ 72 
Table 2-9. Antimicrobial activities of gA mutants with Lys homologs ........................................ 78 
Table 2-10. LC-MS results of gA mutants..................................................................................... 96 
 
 
 
 
 
 
 
 
x 
 
List of Figures: 
Figure 1-1.   Sequence and structure of gA  .................................................................................... 5 
Figure 1-2. Representation of the channel and non-channel conformations of gA in a lipid bilayer
 .......................................................................................................................................................... 6 
Figure 1-3. Schematic representations of different vesicles and vesicle based ion leakage assay  . 7 
Figure 1-4. Schematic representation of a voltage clamp experiment  ............................................ 9 
Scheme 1-1. Synthesis of gA mutants through a fragment condensation method  ........................ 12 
Figure 1-5.  Analytical HPLC traces of two gA-Ar-8 variants made by fragment condensation  13 
Figure 1-6. Representative SEC-HPLC traces separating the monomer and the ds-dimer  .......... 14 
Figure 1-7. Na+ ion detection with the sodium sensitive fluorescence probe SBFI  ..................... 16 
Figure 1-8.  Determination of gA channel activity by Na+ ion leakage assay  .............................. 17 
Figure 1-9. Relationship between peptide concentration and Na+ ion leakage recorded by two   
                   different protocols ....................................................................................................... 19 
Figure 1-10.  Na+ ion leakage caused by membrane disturbance and stable channel formation  .. 20 
Figure 1-11. LC50 values of gA aromatic mutants in Na
+ ion leakage assay  ................................ 21 
Figure 1-12. Correlation between the Log (LC50 ) and physical properties of aromatic residues  . 22 
Figure 1-13. Binding curves of gA-Ar-3 ....................................................................................... 25 
Figure 1-14. Dissociation constants of three gA-Ar mutants  ....................................................... 25 
Figure 1-15. Fraction of Tb3+ leakage from liposomes induced by the gA-Ar mutants  ............... 27 
Figure 1-16. Size distribution of LUVs made of POPC determined by DLS  ............................... 37 
xi 
 
Figure 1-17.  Kinetic profiles of gA-WT induced Na+ ion leakage  ............................................. 38 
Figure 2-1. History of antibiotic discovery and development of antibiotic resistance   ................ 46 
Figure 2-2. Trends of antibiotic resistance and production of new antibiotics .............................. 47 
Figure 2-3.  Proposed mechanism of AMP induced killing of bacterial cells ............................... 48 
Figure 2-4.  Mechanism of gA channel formation in a lipid bilayer  ............................................ 51 
Figure 2-5. Water solubilities of the gA-x mutants  ...................................................................... 53 
Figure 2-6. Apparent dissociation constants (Kd) of the gA mutants  ........................................... 55 
Figure 2-7. K+  ion leakage induced by D-Lys containing gA mutants (gA-x)  ............................. 56 
Figure 2-8. gA mutants induced Tb3+ ion leakage from LUVs  .................................................... 57 
Figure 2-9. CD spectra of gA Figure 2-8. gA mutants induced Tb3+ ion leakage from LUVs  .... 58 
Figure 2-10.  Distinct toxicity profiles of gA-WT and gA-5 against human cancer cell lines  .... 61 
Figure 2-11. Effect of Lys N-methylation on antimicrobial activities of gA mutants  ................. 69 
Figure 2-12. Cellular toxicities of N-trimethylated Lys containing gA mutants  ......................... 69 
Figure 2-13.  Comparison of the Kd values with and without Lys N
-trimethylation  ................... 71 
Figure 2-14. Ion selectivity profiles of gA-xM mutants  ............................................................... 73 
Figure 2-15.  Proton leakage profiles of gA-5 and gA-5M  .......................................................... 74 
Figure 2-16. CD spectra of gA-WT, gA-5M and gA-5 in DPC and SDS micelles  ..................... 76 
Figure 2-17. Structures of Lys homologs and names of corresponding gA mutants  .................... 77 
Figure 2-18. Membrane binding affinities of gA mutants with D-Lys homologs and N-    
                      methylated Lys  ........................................................................................................ 79 
Figure 2-19. Structures of major lipids in a mailman cell membrane, a bacterial plasma 
xii 
 
                      membrane, and important bacterial cell wall carbohydrates components  ............... 82 
Figure 2-20. Targeting the PG headgroup with boronic acid containing peptides  ....................... 83 
Figure 2-21.  Competitive binding assay for determination of boronic acid and 1,2-diol complex   
                      formation  ................................................................................................................. 85 
Figure 2-22.  Inhibition of the ARS-PBA complex formation by different diols  ......................... 86 
Figure 2-23. Synthesis of boronopeptides using SPPS with Fmoc/HBTU chemistry  .................. 88 
Figure 2-24. Illustration of LP3B peptide synthesis  ..................................................................... 89 
Figure 2-25. Comparison of monomeric and polymomeric PBA binding with ARS  ................... 90 
Figure 2-26. Structures and electronic properties of PBA and Tyr  ..................................... 91 
Figure 2-27. Representative bar graph of liposome size distribution determined by DLS  ........... 99 
Figure 2-28. Representative binding curves of gA peptides, fitted with exponential function ... 100 
Figure 2-29. Representative luminescence spectra of the Tb3+/DPA complex leakage .............. 101 
Figure 2-30. Antibiotic activity profiles for (A) gA-WT and (B) gA-5 against bacteria   .......... 103 
 
 
1 
 
Chapter 1. Understanding Channel Formation: Aromatic Modifications of 
Gramicidin A Channel 
 
1.1 Introduction 
1.1.1 Membrane channels 
The cell membrane is not an inert physical barrier but rather a complex and dynamic 
environment that affects the functions and activities of a cell.  The basic composite units of a 
cellular membrane include a variety of lipids, which form a diffusion barrier to ions and polar 
signaling molecules. Transport of these important species is facilitated by a battery of carriers and 
channels. Membrane carriers and ion channels are encoded by numerous gene families, 
comprising about 4% of the genes in the human genome. Approximately 406 genes are known to 
encode ion channels, and 883 to encode a broad variety of carriers, of which 350 are classified as 
intracellular transporters. 1  Most carriers are substrate specific and undergo a series of 
conformational changes to move their substrates across the lipid bilayer. Channels function by 
permitting the passive flow of ions across the membrane at a speed close to the diffusion limit. 
Ion specificities are controlled by the channel diameter or other gating mechanisms. Ion channels 
are found to be responsible for signaling in the nervous system, coordinating muscle contraction, 
and transport of messenger molecules. Defective ion channels are known to be responsible for 
diseases such as cystic fibrosis, renal disorders, and certain types of hypertension, osteoporosis, 
and conditions such as deafness and reduced sleep.2 ,3  Because of their important biological 
functions, they have become important drug targets. In the past few decades, great efforts have 
been made to understand the structure, the biochemical function and mechanisms of these 
channels. Recent success in the crystallographic analyses of ion channels, such as the KscA 
potassium channel, has provided exciting insights into ion channel structures and functions. 
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However, it is becoming increasingly clear that the static structures obtained by crystallography 
may not be sufficient to represent proteins, especially the conformational changes in a functional 
channel.  
The use of model membranes allows for simplification of the biological membrane, while 
still providing a dynamic environment for detailed characterization of ion channels. As 
recombinant membrane proteins are often difficult to be produced in its active conformation in 
high yield and purity, small peptide channels are also considered to be attractive models due to 
their simplicity in synthesis and purification. 
 
1.1.2 Aromatic residues in membrane proteins 
Long before the first high resolution structure of a membrane channel was obtained, the 
availability of amino acid sequences for many membrane channel proteins opened up the 
possibility of structural and functional studies through computational modeling and topology 
prediction. As the number of available structures in the Protein Data Bank increases, more is 
learnt through rigorous statistical analyses. In general, membrane proteins are divided into two 
basic structural categories: helical bundle and -barrel. Nevertheless, membrane proteins share 
common characteristics of a belt of hydrophobic (mainly aliphatic) amino acids in the middle, 
buried in the hydrophobic core of the lipid bilayer and flanked by two “aromatic girdles” 
composed of tryptophan (Trp) and tyrosine (Tyr) residues around the membrane-water interfaces. 
This presents a hydrophobic match of the protein architecture and the membrane environment.4 ,5  
It has been proposed that the aromatic residues can participate in cation- interactions, polar-
polar interactions, and hydrogen bonding interactions with the lipid head-groups, water molecules, 
or with each other. Therefore, they can promote protein association and lock the protein structure 
by anchoring around the membrane-water interfaces.  Mutagenesis studies have also suggested 
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the importance of these aromatic residues in terms of protein stability and activity.4 ,6 ,7  In 
summary, aromatic residues (Trp and Tyr) appear to be important and special among the twenty 
natural amino acids. We intend to probe the chemical basis of aromatic residues as membrane 
anchors and further propose that unnatural amino acids could serve as powerful tools in this 
investigation.  
 
1.1.3 Gramicidin A channel 
Gramicidin is a heterogeneous mixture, with gramicidin A, B, and C making up 80%, 6% 
and 14% respectively. It was  first identified as an antibiotic produced by a culture of B. brevis 
isolated from soil samples by Dubos et al.8  Among the mixture, gramicidin A (gA), the peptide 
of interest, has fifteen amino acids, consisting of D- and L- amino acids at alternate positions 
(formyl-L-Val-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-Val-L-Trp-D-Leu-L-Trp-D-Leu-L-Trp-D-Leu-
L-Trp-ethanolamine). It is one of the most hydrophobic sequences reported and is essentially 
insoluble in aqueous solution (< 50 nM). 9  In a lipid bilayer, the peptide folds into a -helix. Due 
to the alternating D- and L- residues, all side chains project to the same side of the peptide strand, 
which, upon peptide folding, becomes the exterior of gA channel and interacts with the 
hydrophobic core of the bilayer. The interior of the -helix is formed by the polar peptide 
backbone hydrogen bonding network.  Two folded monomers in the two leaflets of a membrane 
bilayer dimerize to form a head-to-head transmembrane channel (Figure 1-1). This dimeric 
channel is stabilized by six intermolecular hydrogen bonds and the channel is gated by the 
association and dissociation of the monomers (Figure 1-1b).10  The size of the channel pore 
(diameter about 4 Å) is only large enough to accommodate monovalent cations (Cs+, Rb+, K+, Na+, 
Li+, NH4
+, H+) and water molecules but not cations with higher oxidation state or anions. 11 ,12 ,13  
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The vertical length of the dimer is about 26 Å, which is long enough to span most lipid bilayer 
(Figure 1-1).14   
Besides the -helical channel conformation found in membranes, other conformations 
have been observed when the gA peptide is dissolved in a variety of organic solvents.15 ,16   
Among them, the most dominant and stable one is an intertwined double helix (ds-dimer), known 
as the non-channel conformation. This ds-dimer is stabilized by 28 intermolecular hydrogen 
bonds (Figure 1-2).5  It was found that polar solvents promote the monomer formation, while the 
ds-dimer is favored in most nonpolar solvent.17  Interestingly, upon binding and insertion into a 
lipid bilayer, the peptide conformation is determined by the solvent in which the peptide is 
dissolved prior to mixing with lipids. As described above, the gA channel can only be formed by 
the monomers. Therefore, the amount of monomers, in a peptide stock solution determines the 
amount of peptides available for potential channel formation. 
gA has four Trp residues at positions 9, 11, 13 and 15. In the ds-dimer non-channel 
conformation, Trp residues are more evenly distributed along the vertical axis of the membrane 
whereas in the -helical channel, Trp residues are clustered at the end of the -helix and towards 
the membrane-water interface (Figure 1-2). Early studies suggested that these Trp residues were 
critical for maintaining the structure and function of the channels. For example, the channel 
conductance decreases upon substitution of one or all of the Trp residues by glycine, 
phenylalanine, or naphthylalanine.17 ,18 ,19  These mutations also promote the non-channel 
conformation.  
As described above, gA shares several important features with other channels from 
natural sources: (1) it possesses a well-defined structure that allows for the rapid passage of 
specific ions; (2) it presents a high abundance of aromatic residues, Trp to be specific, which 
locate at the membrane-water interfaces; (3) it has a known gating mechanism. Compared to 
5 
 
other membrane channels, gA offers several experimental advantages because of its small size, 
easy accessibility, and a well characterized structure and mechanism of action. We therefore 
chose gA as a model peptide, from which we learned useful information that could be applicable 
to the understanding of more complex membrane channels, and to future efforts in membrane 
channel engineering.  
 
 
 
Figure 1-1.  a) Sequence of gA in single letter code (the D-amino acids were labeled by the italic 
“d”) and cartoon representations of the -helical dimeric channel (bottom, PDB: 1MAG, derived 
from solid-state NMR data in lipid bilayer, side view on the left and top view on the right); b) the 
gating and channel formation equilibration. A cartoon representation showing the peptide in a 
lipid bilayer can be found in Figure 1-2. 
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Earlier studies using gA as a model peptide are rather limited, as the reported 
modification on gA only substituted the Trp residues with simple hydrophobic amino acids. 
While Trp has the largest nonpolar surface area among the twenty natural amino acids, it 
possesses a polar NH moiety that can serve as hydrogen bond donor. This unique amphipathic 
character may account for its preference for the membrane-water interface. To test our hypothesis, 
a series of amphipathic aromatic amino acids were chosen to be incorporated into the gA peptides. 
The channel activities of these gA mutants were determined by ion leakage assay. Activity 
comparison and detailed analyses were performed to understand the structure activity relationship 
of gA channel formation.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. A schematic representation of the channel (-helical dimer, left) and non-channel 
(intertwined double helix, ds-dimer, right) conformations of gA, indicating the location of Trp 
residues in a membrane bilayer. The membrane axis is represented by double headed arrows and 
the center of the bilayer is marked by a dotted line. The graph is reconstructed from reference 5.   
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1.1.4 Membrane channel characterization 
 
 
 
Figure 1-3. a) Schematic representations of different vesicles; b) schematic representation of ion 
channel leakage experiments. A pH gradient results from addition of extravesicular NaOH 
solution. The charge caused by H+ efflux or OH- influx is compensated by anion influx or proton 
efflux, mediated by a transmembrane channel such as gA. The increase in intravesicular pH, 
monitored by the entrapped pH-sensitive fluorophore, HPTS, reflects the electrolyte exchange 
rate. Figure b was reconstructed from reference 20.  20  
 
Characterization of membrane proteins is generally more complicated then soluble ones 
due to peptide/protein aggregation and the heterogeneity introduced by the mixture of membranes 
and aqueous solution. Model membranes have been widely used as mimics of the native 
membrane environment. There are two main experimental approaches to the study of ion 
channels: vesicles and planar bilayer membranes.  Vesicles (or liposomes) are prepared by 
dispersion of lipids in an aqueous buffer to form spherical closed-shell structures ranging from 
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below 20 nm to above 1 m in diameter. They can have one (unilamellar, SUV and LUV) or 
more layers  (multi-lamellar, MLV) of bilayer membrane(Figure 1-3a).21  The internal aqueous 
volume is therefore fixed and separated from the external medium. A wide range of membrane 
impermeable reporters can be trapped in the interior of this robust vesicle structure. The external 
environment can be readily adjusted by size-exclusion gel filtration. The size of the vesicles can 
be dictated by the pore size of the filtering membrane, through which the vesicles pass 
repetitively.  The vesicles can be composed of various lipids and in different ratios as designed, to 
mimic the lipid composition of cells of interest. 22 ,23  
Membrane channels promote the translocation of ions from one side of a membrane to 
the other. The interior volume of a typical vesicle is on the order of femtoliters, much smaller 
than the bulk exterior solution. Therefore gain or loss of a relatively small amount of ions is 
sufficient to produce a very large change in the concentration of compound inside the vesicle. 
Consequently, any techniques that can measure ionic concentrations on one or both sides of the 
vesicles can be used to determine the activity of an ion channel. Several ion selective 
fluorescence probes have been developed for this purpose, examples including the pH- sensitive 
probe HPTS (8-hydroxypyrene-1,3,6-trisulfonic acid, Figure 1-3b) and sodium sensitive 
probes.20 ,24 ,25 ,26 ,27  In addition, 23Na-NMR can be used to determine the translocation rate through 
a line-shape analysis.28   
Planar bilayers can be formed across a small aperture in a glass barrier between two 
aqueous electrolyte solutions.  Planar bilayer membranes are ideal for the study of the ion channel 
conductance using a technique known as voltage clamp, developed by Erwin Neher and Bert 
Sakmann in the late 1970s early 1980s . In this technique, a constant transmembrane potential is 
applied and the resultant current changes are monitored as a function of time (Figure 1-4).  The 
membrane itself is a good resistor.  Therefore, in the absence of an open channel, very little 
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current is observed. When a single ion channel opens, the ion flux in response to the applied 
potential produces a current in the range of pico- to nanoamps. This ‘‘opening’’ appears as a step-
change in the conductance of the membrane. When an active channel ceases to function, the ionic 
current falls abruptly back to the baseline of the unaltered bilayer membrane. This step-change 
behavior is a unique and unmistakable signature of a single ion channel. The voltage clamp 
technique directly observes redundant ion channels individually. The collective properties of 
channels are assessed by statistical techniques to determine the specific conductance of the 
channel, its open probability, the voltage-dependence of the conductance, and the ionic selectivity 
of the transport. Due to the requirement of the high resistance membrane to achieve a low 
background signal, the lipid composition is limited to lipids with branched tails. 
 
 
Figure 1-4. Schematic representation of a voltage clamp experiment. A cuvette (a), with a small 
hole cut into one face, is immersed in an electrolyte (b) and the bilayer is formed by painting lipid 
across the hole. Electrical contact with Ag/AgCl reference electrodes (e) in a reference electrolyte 
(d) is via Agar salt-bridges (c). A potential is applied and the current measured as a function of 
time. Channels appear as abrupt transitions. Figures reconstructed from reference 21. 21  
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In summary, the patch clamp technique focuses more on the characterization of 
individual ion channels embedded in the planar lipid bilayer. It requires experienced personnel, 
special equipments, and a low noise environment. In contrast, the vesicle-based leakage technique 
focuses more on the bulk properties and the average effects of thousands of channel forming 
molecules, and importantly the assay is much more applicable and flexible. 
In my project, we are trying to identify better ion channels that can cause ion leakage and 
ion equilibration induced cell death more efficiently. Therefore, in the characterization of our gA 
mutants, the vesicles based ion leakage assay is used primarily.  
 
1.2 Synthesis and characterization of aromatic mutations of gA channel 
1.2.1 Selection of aromatic residues and peptide synthesis 
A library of natural and unnatural aromatic amino acids was chosen to substitute the Trp 
residues in the wild-type gA. In contrast to early reported mutations, in which Trp was substituted 
by nonpolar amino acids (Phe, naphthylalanine, Ala, Gly), the aromatic amino acids we have 
tested possess amphiphilic side chains (Table 1-1).  Among them, the phenylalanine modification 
has been heavily characterized and serves as a control peptide in our system. It was suggested that 
the more Trp residues were substituted with Phe, the more channel conductance decreased.29  In 
our designed gA mutants, the Trp at position 15 was kept as a reporter for peptide concentration 
calibration, and binding constant determination. It also simplifies the peptide synthesis, as all 
peptides can be loaded on Fmoc-Trp-Wang resin. Substitutions of the other three Trp residues at 
positons 9, 11, 13 would provide a wide window for characterization and comparison.   Important 
properties of these amino acids were calculated by computational simulation in Spartan (Table 1-
1).  While similar in size, these aromatic residues varied in electronic properties, which were 
proposed to be important for the preferential interface localization of aromatic residues.9 ,30  The 
wild-type gA is commercially available and other mutants were synthesized through solid phase 
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peptide synthesis (SPPS) using the standard Fmoc/HBTU chemistry. DMF was used as solvent. 
The N-terminal formyl-valine was pre-made and used as a building block in SPPS. gA has one of 
the most hydrophobic sequences known. Linear synthesis of the whole peptide was found to be  
 
Table 1-1. Structures and important properties of the aromatic residues used in modification 
 
12 
 
problematic. Except the 7-azatryptophan (AW) containing mutant (gA-Ar-3), a mixture of 
fragments was observed in the LC-MS analysis for all other gA mutants (data not shown). 
Therefore, a fragment condensation method was applied instead (Scheme 1-1). To be more 
specific, two fragments of the peptide were synthesized through SPPS, in which the N-fragment 
contains the first 10 amino acids (formyl-L-Val1 to D-Leu10) and the C-fragment contains the 
remaining five amino acids (Ar11 to Trp15-ethanolamine). The N-fragment was cleaved off the 
Fmoc-D-Leu Wang resin by reagent K to expose a free carboxylic acid. The C-fragment was 
cleaved off the resin by ethanolamine.  Both fragments were then precipitated from the cleavage 
solution by water.  The two fragments were then dissolved into a solvent of DCM/DMF (v/v: 3/1), 
and the amide bond formation was accomplished by using HATU/HOAt activation. When the 
reaction is complete, DCM was removed and the full sequence peptide was precipitated from 
DMF with water. The crude material was purified by RP-HPLC and confirmed by LC-MS.   
 
formyl-Val-XXX-D-Leu(10)
reagent K (80% TFA, 5% H2O, 2.5% EDT,
5% Thioanisole and 7.5% Phenol, 2 hrs r. t.
deionized water precipitation
formyl-Val-XXX-D-Leu(10)-COOH
NH2-Ar (11)-XXX-Trp (15)
SPPSFmoc-D-Leu
Fmoc-Trp SPPS
40 % ethanolamine in DMF,
 55 oC, 5 hrs
deionized water precipitation NH2-Ar (11)-XXX-Trp (15)-NHCH2CH2OH
N-fragment
C-fragment
HATU/HOAT, DIPEA
DCM/DMF (3/1), r.t
HPLC monitor conversion
water precipitation
gA-Ar-mutants wang resin
 
 
Scheme 1-1. Synthesis of gA mutants through a fragment condensation method. 
 
There is a possibility of racemization when fragment condensation happens between two 
polypeptide fragments through amide bond formation between the activated carboxylic acid and 
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amine. To confirm the success of our method, two variants of gA-Ar-8 with D-Leu (gA-Ar-8) and 
L-Leu (gA-Ar-8L) at position 10 respectively were made under the exact same conditions and 
analyzed with LC-MS.  Racemization in our ligation reaction is negligible.  The two peptides 
were well resolved on the C4 column (retention times 17.87 mins for gA-Ar-8 and 19.15 mins for 
gA-Ar-8L) and only one dominant peak was observed in each reaction (Figure 1-5).  
 
 
 
Figure 1-5.  Analytical HPLC traces of the two gA-Ar-8 variants gA-Ar-8 (insert graph, D-
Leu10) and gA-Ar-8L (L-Leu10).   The mass of the species represented by each peak is marked in 
the figure.  
 
1.2.2 Characterization of gA mutants with aromatic modifications 
 
14 
 
 
 
Figure 1-6. Representative SEC-HPLC traces separating the monomer and the ds-dimer (a) gA-
WT incubated in MeOH reported as monomer; b) gA-WT incubated in THF for two days, 
reported as a mixture of monomer and dimer.  
 
Firstly, the peptide conformation (monomer vs ds-dimer) in DMSO was determined by 
size exclusion high performance liquid chromatography (SEC-HPLC).  A solution of a peptide in 
DMSO was injected onto the SEC column and then eluted with THF isochromatically with a flow 
rate of 1 mL/min.  The interconversion between the two conformations (monomer and ds-dimer) 
is too slow to be noticed on the experimental time-scale. 31 The percentages of the ds-dimers and 
a
) 
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-helical monomers eluted from the column do not differ from the values originally present in the 
solution.17  The eluting peptides were detected at two wavelengths (280 nm and 254 nm) and the 
relative amount was calculated by the integration area of each peak. 17  The retention time of the 
gA monomer and ds-dimer was calibrated by that of gA-WT (Figure 1-6, Table 1-2). Our results 
were consistent with previous reports: gA-WT dissolved in MeOH exists as monomers, and when 
gA-WT is incubated in THF, the peptide exists as a mixture of monomers and ds-dimers. Based 
on the mechanism of size exclusion chromatography, we assigned the first peak as the ds-dimer, 
which is larger and less likely to be trapped into the pore of the solid phase. The retention times 
for the ds-dimer and monomer are 7.9 minutes and 8.6 minutes respectively. In DMSO, all gA 
mutants we made exist as a monomer. 
 
Table 1-2: The retention times of gA mutants off the SEC-HPLC 
peptide 
Retention 
Time 
(tR/mins) 
Area % peptide 
Retention 
Time 
(tR/mins) 
Area % 
gA-WT 8.7 100% gA-Ar-5 [a] 8.8 95% 
gA-Ar-2 8.7 100% gA-Ar-6 8.7 100% 
gA-Ar-3 8.5 100% gA-Ar-7 8.6 100% 
gA-Ar-4 8.5 100% gA-Ar-8 8.5 100% 
 
[a] about 5% of the ds-dimer, which had a retention time of  8 mins,  was observed in the gA-
Ar-5 DMSO solution  
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Figure 1-7. Na+ ion detection with the sodium sensitive fluorescence probe SBFI. a) Binding 
mechanism of SBFI and Na+ ion; b) Excitation spectra of SBFI (5 M in 10 mM MOPS buffer, 
pH 7.05), in the absence of monovalent ions (black), in the presence of 135 mM Na+ ions (blue) 
or 135 mM K+ ions (red); c) Determination of the SBFI-Na+ dissociation constant in absence 
(blue) or presence (black) of K+ ions. The y-axis represents the fluorescence ratio of 340 nm over 
380 nm in the excitation spectra( em = 505 nm).  
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Figure 1-8.  Determination of gA channel activity. a) Representative scheme of the ion leakage 
assay. The counter ions Cl- are not shown in the graphs. b) fluorescence detection of Na+ 
transport. Condition: 500 M LUVs POPC  20 M SBFI, 135 mM KCl, 10 mM MOPS buffer, 
pH 7.0, in which symbol means encapsulating; outside buffer: 10 mM MOPS, 135 mM NaCl 
Fluorescence spectra of 1 nM (black) gA-WT addition (known to have no effect on liposomes) 
and 5 M (red) gA-WT addition, which is known to induce complete ion leakage from liposome. 
The spectra were recorded at 505 nm; c) ratio of I340/I380 in the excitation spectra shown in b.  
 
To test channel activities of these gA mutants, a leakage assay was established. In the 
assay, a sodium sensitive fluorescent dye (SBFI, sodium-binding benzofuran isophthalate) was 
encapsulated inside the large unilamellar vesicles (LUVs) to report interior Na+ concentration 
(Figure 1-8). SBFI (Figure 1-7a) is a membrane impermeable sodium indicator consisting of 
fluorophores linked to the nitrogens of a crown ether, with a cavity size that confers selectivity 
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for Na+. Upon sodium binding, the excitation peak narrows significantly and blue shifted, causing 
a large change in the ratio of 340nm/380nm at the excitation spectra (em = 505 nm, about 2.5 fold 
increases at 135 mM Na+, Figure 1-7b). This assay provides sufficient spatial and temporal 
resolution of Na+ concentration under physiological conditions.27 ,31  Furthermore, the interfering 
effect of K+ ion in solution was evaluated. In contrast to the Na+ addition, the effect of 135 mM 
K+ ions added to the SBFI solution is minimal (Figure 1-7c). The presence of K+ ions only shifts 
the dissociation constant from 7.0 mM to 25.1 mM, which guarantees 100% occupation of SBFI 
when 135 mM Na+ is used in the leakage experiments even in presence of K+ (< 135 mM). 
In the leakage assay (Figure 1-8), a solution of SBFI (20 M and 135 mM K+ ion in 10 
mM MOPS, pH = 7.0) was encapsulated into POPC LUVs, which are suspended in a buffer 
containing 135 mM Na+ (10 mM MOPS, pH = 7.0). As a result, there would be no osmotic 
pressure while a Na+/K+ ion gradient is built across the lipid bilayer. When a gA mutant is added 
into the solution, the active peptide binds onto the lipid bilayer and forms a channel. Upon 
channel formation, Na+ ion diffuses across the lipid bilayer along the ion gradient (from the 
outside to the inside), and binds with the encapsulated SBFI, eliciting a shift of the SBFI 
fluorescence excitation spectrum (Figure 1-8b) and a 2.3 fold increase in the I340/I380 nm ratio 
(Figure 1-8c).  
To further confirm the reliability of this leakage assay in terms of measuring ion diffusion 
through stable membrane channels, we performed the assay following two protocols with 
different orders of peptide addition and Na+ ion gradient formation.  Liposomes encapsulating 
SBFI (20 M) and KCl (135 mM) were suspended in a MOPS buffer containing either 135 mM 
NaCl (system I) or 135 mM KCl (system II).  In system I, a transmembrane Na+ gradient exists 
before gA peptide addition. In contrast, NaCl was added to generate the transmembrane Na+ ion 
gradient in system II 2 hours after the peptide addition, at which point the peptide folding and 
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translocation is complete. We would expect similar observations in both systems when stable 
channels, like gA-WT, are formed. In system I, gA-WT addition induced Na+ ion leakage and 
changed the excitation spectrum. A concentration profile of gA-WT was generated (Figure 1-9a). 
In system II, however, upon peptide addition, no change in the fluorescence spectra was observed 
due to the absence of Na+ ions. This result suggests that encapsulated SBFI reports Na+ ion 
specifically, and a high concentration of K+ ion does not affect the fluorescence signal. A similar 
concentration profile was then observed in system II upon NaCl addition (Figure 1-9b). Moreover, 
similar LC50 (the peptide concentration required to induce 50% of ion leakage) values were 
obtained in the two systems. If ion equilibration is only caused by membrane disturbance during 
peptide binding and/or translocation, there would be negligible fluorescence change in the system 
II.   
 
Figure 1-9. Relationship between peptide concentration (gA-WT) and the percentage of Na+ ion 
equilibration through the transmembrane gA channel.  The Na+ ion leakage was determined in a) 
system I, in which Na+ ion gradient exists before peptide addition or b) system II, in which a Na+ 
ion gradient is generated 2 hours after peptide addition. LC50 values were obtained by fitting the 
concentration profile into an exponential function.  
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Figure 1-10. Relationship between peptide concentration and the percentage of Na+ ion 
equilibration caused by a) a stable channel forming peptide gA-Ar-8 and b) gA-Ar-8L that does 
not form stable -helical channel. 
 
The alternating D- and L- amino acids arrangement is considered to be important to gA 
channel formation.4  We expect gA-Ar-8L (formyl-L-Val-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-
Val-L-4Pal-L-Leu-L-4Pal-D-Leu-L-4Pal-D-Leu-L-Trp-ethanolamine) to be incapable of forming 
stable channels.  Consistent with our expectation, no Na+ ion equilibration is observed when gA-
Ar-8L is added into system II. gA-Ar-8L only causes Na+ ion leakage when it is added to system 
I, where the Na+ ion gradient exists before the peptide addition.  In contrast, similar concentration 
profiles were observed in both systems for gA-Ar-8 (formyl-L-Val-Gly-L-Ala-D-Leu-L-Ala-D-Val-
L-Val-D-Val-L-4Pal-D-Leu-L-4Pal-D-Leu-L-4Pal-D-Leu-L-Trp-ethanolamine). We concluded that 
Na+ leakage caused by gA-Ar-8L in system I is caused by membrane disturbance due to peptide 
binding and/or translocation. The lack of gA-Ar-8L induced ion leakage in system II suggested 
that Na+ ions cannot diffuse through the bilayer when no stable channel is formed, and peptide 
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folding and translocation are complete after 2 hours (Figure 1-10b). In summary, the leakage 
assay performed in system II is a reliable method to evaluate ion channel formation. It reflects the 
amount of stable channels formed on the vesicles instead of nonspecific membrane disturbance.  
 
 
 
Figure 1-11. LC50 values of gA aromatic mutants in causing Na
+ ion equilibration across a POPC 
lipid bilayer. The values were obtained from fitting the concentration profile of the SBFI leakage 
assay with an exponential function in system I.  The structures of the aromatic residues are 
labeled on top of each bar. Similar LC50 values were obtained in system II.  
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Figure 1-12. Correlation between the Log (LC50 ) values and physical properties of corresponding 
aromatic amino acids. Plots are shown for the Log (LC50 ) values of gA-Ar-(WT-8) vs (a) LogP, 
(b) magnitude of dipole moment, (c) the linear combination of  dipole moment and 
LogP(s1 dipole + s2 Log P, in which s1 and s2 are the slope in a) and b) respectively, (d) the 
synthetic parameter (s1Log P + s3cos  dipole + s4sin  dipole), in which s3 and s4 are the 
slopes when Log (LC50 ) values were plotted vs cos  dipole(0.0498)  and sin  dipole (0.0657) 
respectively. Also plots for Log (LC50 ) of gA-Ar-(6-8) vs (e) cos  dipole, (f) sin  dipole.  is 
the angle between the calculated dipole moment and the C-C carbon- carbon bond.  
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The channel formation efficiency of the gA mutants listed in Table 1-1 was evaluated by 
the leakage assay described above. Fitting the concentration profile into an exponential function 
yielded the LC50 values (Figure 1-11). Values of Log (LC50) were plotted against the calculated 
physical properties of corresponding aromatic residues. Poor correlations between Log (LC50) and 
Log P and dipole moment (Log P, Figure 1-12a, R2 = 0.055; dipole moment, Figure 1-12b, R2 = 
0.018) suggested that no single factor is enough to determine the peptides’ channel formation 
potency. Better correlation was observed when a linear combination of dipole moment and LogP 
was considered (Figure 1-12c, R2 = 0.20). When the dipole moment direction was added to the 
combination, the correlation was further improved (Figure 1-12d, R2= 0.32). The directional 
dipole is quantified by the angle between the dipole and the C-C bond.  Components at 
directions along and perpendicular to the C-C bond were considered separately (Table 1-1) in 
calculating the synthetic factor (Figure 1-12d). However, this correlation is still not good enough 
to reliably predict channel activity of a gA-Ar mutant from the dipole and LogP value of 
corresponding aromatic residues.  When the gA-Ar-(6-8) are considered separately, a positive 
correlation was observed between the values of Log (LC50) and the calculated cos  dipole but 
not sin  dipole (Figure 1-12e, Figure 1-12f).  It suggests that the component of the dipole along 
the C-C bond plays a significant role when regioisomers are considered. We were not able to 
evaluate the contribution from hydrogen bonding capability and amphiphilicity to channel 
activity as it is hard to quantify these two factors. 
Additional interesting phenomena should be noticed. gA-Ar-4 showed higher channel 
potency than the gA-WT, and gA-Ar-5 showed comparable activity with gA-WT. These 
observations seem to be inconsistent with earlier reports that gA-WT shows the highest single 
channel conductance. 9 ,11 Substitution of Trp with Phe decreases the single channel conductance. 
However, in the voltage clamp assay, peptides were added from both sides of the planar bilayer to 
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close proximity of the membrane. The assay records the channel conductance of individual 
channels. Therefore, the results do not account for the amount of membrane bound peptides and 
peptide folding and translocation from the outer leaflet to the inner leaflet. We propose that the 
discrepancies might be attributed to the differences in peptide membrane binding affinities and/or 
the folding propensities of these mutants.  
We then measured the dissociation constants of these peptides with POPC vesicles (Kd in 
lipid/peptide L/P ratio, Figure 1-13, Figure 1-14) through titration. Various amounts of lipids 
were titrated into a solution of 1M gA mutant and the Trp fluorescence was monitored. Upon 
binding to a hydrophobic membrane, the emission of Trp fluorescence blue shifts (from 350 nm 
to 330 nm). This fluorescence shift has been widely used to monitoring peptide-membrane 
binding.  Unfortunately, only two peptides (gA-WT and gA-Ar-2) have strong enough Trp 
fluorescence for reliable and conclusive recording. The quantum yield of 7-azatryptophan (7-AW) 
increases from 0.01 in aqueous solution (pH 7) to 0.25 in acetonitrile.32  Therefore the 
fluorescence intensity at 380 nm (max of 7-AW) instead of Trp fluorescence was used to report 
membrane binding of gA-Ar-3 (Figure 1-13). None of the other five peptides showed reliable 
fluorescence at a concentration relevant to the leakage assay (3 M was the highest used). There 
might be energy transfer between the closely positioned Trp and other aromatic residues, which 
quenches the Trp fluorescence. The gA-Ar mutants have similar hydrophobicities as their 
retention times on the C4 HPLC column are very similar. Importantly, the three mutants 
mentioned above showed Kd values smaller than 50 in L/P ratio (Figure 1-14). Because all 
leakage assays were performed at L/P ratio higher than 1,000, which is about 20 times higher than 
the Kd values, we believe that all peptides are bound onto the vesicles in the leakage assay. 
Therefore the differences in channel activity determined by Na+ leakage assay are most likely not 
25 
 
due to membrane binding, but rather due to  the folding propensity of  gA-Ar mutants in 
membranes.  
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Figure 1-13. Binding curves of gA-Ar-3, plotting the fluorescence intensity at 380 nm over the 
L/P ratio (filled square). The apparent dissociation constant was obtained by fitting into an 
exponential function. 
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Figure 1-14. Dissociation constants of three gA-Ar mutants. The values of gA-WT and gA-Ar-2 
were obtained by fitting I330 nm /I 350 nm of Trp fluorescence against the L/P ratios into an 
exponential function and the value of gA-Ar-3 is determined by 7-AW fluorescence at 380 nm. 
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Circular dichroism (CD) spectroscopy has been a widely used method in determining 
protein secondary structure. Unfortunately, the actual shape and magnitude of the CD signal can 
be significantly affected by the number and the type of aromatic amino acids present. The 
ellipticity that arises from aromatic amino acids are highly dependent on their mobility, the nature 
of their environment (hydrogen bonding, polar groups and polarizability) and their spatial 
disposition in the protein.33 ,34  Therefore, structure charaterization of these gA mutants via CD 
has been difficult, due to the high abundance (4 out of 15 amino acids) of aromatic residues. This 
is also supported by the inconsistencies in the reported gA CD spectra,11 ,17 ,35  as well as our own 
experience with poor reproducibility of CD data for the gA mutants (data not shown).  
As an alternative, we applied an indirect method to probe the structures of these gA 
mutants. This was assessed by the ion selectivity of the gA mutants, which was measured with 
liposomes encapsulating K+ or Tb3+ respectively.  If the channel structure is similar to that of gA-
WT, they should display ion specificity, allowing only small monovalent ions (e.g., Na+) to pass 
through. The leakage of Tb3+ from liposome was monitored by the luminescence of Tb/DPA 
complex.36  To be more specific, Tb3+ ions were encapsulated into LUVs. If Tb3+ ions diffuse to 
the exterior solution through the channel, the Tb3+ luminescence intensity at 490 nm increases 
upon binding to the membrane impermeable dipicolinic acid (DPA) in the external buffer. Under 
the same experimental conditions, all gA mutants show potent activity in Na+ equilibration, yet 
no Tb3+ leakage is observed at concentrations that cause complete K+ release (Figure 1-11, Figure 
1-15). The selective transport of K+ ions indicates that the active gA channels have wild type like 
structures. However, this assay fails to quantify the amount of active gA channels. Since all 
peptides are bound onto the membrane under experimental conditions, we hypothesize that it is 
the degree of peptide misfolding in membrane that accounts for the range of activities in the Na+ 
ion leakage assay. Detailed structure analyses of these mutants need to be done to prove our 
hypothesis.  
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Figure 1-15. Fraction of Tb3+ leakage from liposomes induced by the gA-Ar mutants. The 
complete release of Tb3+ ions was triggered by 0.1% of TX-100, and the DMSO addition was 
considered as the negative control.  
 
1.3 Summary 
In summary, we have evaluated the ion channels formed by gA-Ar mutants with the Trp 
residues at positions 9, 11, 13 replaced by seven different aromatic amino acids.  Compared to the 
previous work, the aromatic amino acids we selected are largely amphiphilic, and therefore better 
mimics of Trp than simple hydrophobic aromatic residues. The potential of these aromatic 
residues to mediate gA folding was analyzed and compared. We have successfully set up a 
liposome-based leakage assay to determine the channel induced Na+ ion leakage, which reflects 
the channel formation efficiency of our designed gA mutants.  As three of the aromatic residues 
cannot serve as hydrogen bond donors, which was believed to be crucial for Trp to interact with 
the phospholipids, we conclude that a hydrogen bond donor is not essential for aromatic amino 
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acid as a membrane anchor. The direction of the dipole moment for amphiphilic aromatic 
membrane anchors appears to be important for gA channel activities.  Detailed structure analyses 
need to be performed to fully understand the structure activity relationship of these gA-Ar 
mutants.  
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1.4 Materials and methods 
I. General materials and methods  
Fmoc-Trp-Wang resin, Wang resin and all Fmoc-protected amino acids were purchased 
from either Advanced Chemtech (Louisville, KL) or Chem Impex Int. Inc (Wood Dale, IL). 
Unprotected valine, wild-type gA and other chemicals were obtained from Sigma-Aldrich or 
Acros Organics unless otherwise indicated. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), was purchased from Avanti Polar Lipids (Alabaster, AL). SBFI tetraammonium salt was 
purchased from Invitrogen (Eugene, OR).  Peptide synthesis was carried out on a Tribute peptide 
synthesizer (Protein Technologies, Tucson, AZ). 1H-NMR data were collected on a Varian 
Gemini 500 MHz NMR spectrometer. LC/MS (ESI+) data were generated by the Boston College 
mass-spectrometry facility(Waters MS system). The protein concentration of all samples used in 
this study was determined by measuring their absorbance at 280 nm on a Nanodrop 2000c 
UV/Vis spectrometer. The liposomes were prepared by using Liposofast Mini Extrusion system 
(Avanti Polar Lipids, Alabaster, AL) and following the procedure posted by Avanti Polar Lipids.  
The physical properties (dipole moments, LogP, and surface areas )of the 
aromatic amino acids side chain was calculated with Spartan’10 (Wavefunction, Inc.) 
using the PM3 semi-empirical model and the results were listed in Table 1-1.   
 
II. Peptide synthesis 
1. Synthesis of formyl-L-valine 
Acetic anhydride (4 mL, 0.04 mol) was added dropwise to a solution of L-valine (1 g, 
8.35 mmol) in formic acid (12 mL, 0.32 mol) while stirring on ice. The mixture was then warmed 
up to RT and kept stirring for 24 hours before the solvent was removed by rotary evaporation 
under high vacuum.  The formyl-valine was recrystallized from ethyl acetate and the desired 
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product was obtained as a white solid. Yield: 0.78 g (64%) 1HNMR (500 MHz, [D6] Acetone, 
25 °C, TMS ):  = 8.22 (s, 1H), 7.41(b, 1H), 4.50 (m, 1H), 2.22 (m, 1H), 0.98(m, 6H).  
 
2. Synthesis of Fmoc- L-7-azatryptophan 
The synthesis of L-7-azatryptophan (7-AW) was achieved through an enzymatic reaction. 
37  Firstly, the tryptophan synthase was expressed in Escherichia coli (E. coli). A sample of E. coli 
pre-transformed with pSTB7 was received as a gift. This was plated onto solid LB supplemented 
with ampicillin (100 g/ mL). Following incubation of the plate at 37 oC overnight, a single 
bacterial colony was picked up and used to inoculate sterile LB medium (10 mL) for 6 hours 
before pouring this pre-culture to 500 mL sterilized LB medium supplemented with ampicillin. 
Next, the culture was incubated on an orbital shaker with 200 rpm, at 37 oC. After 12 hours, the 
cultures were centrifuged (15,000 rpm, 4 oC, 20 mins). The cell pellet was re-suspended in a 
buffer (500 mM trishydrochloride, 5 mM EDTA, 10 mM mercaptomethanol, 1 mM PESF, 0.1 
mM PLP, pH 7.8). The cells were lysed by sonication, centrifuged (10,000 rpm, 4 oC, 20 mins) to 
remove cell debris, and the crude supernatant (solution of tryptophan synthase) can be used in the 
catalytic reaction without further purification.  
L-Serine (0.127 g, 1.21 mmol), 7-azaindole (1 eq, 143 mg, 1.21 mmol), and PLP (0.8 mg, 
0.003 mmol) were mixed in 50 mL of buffer ( 0.1 M KH2PO4, pH 7.8). The solution was cooled 
to 5 oC, cell lysate ( 2 mL at 5 oC) was then added to the flask. Reactions were incubated at 37 oC 
for 24 hours.  The reaction mixture was filtered and extracted with ethyl acetate (2  50 mL) to 
remove any un-reacted indole and recover the starting materials. The aqueous layer was subjected 
to RP-HPLC purification with a C18 column to obtain the purified 7-azatryptophan.  7-
azatryptophan (100 mg, 0.48 mmol) dissolved in water was mixed with a solution of Fmoc-OSU 
(135 mg, 0.40 mmol) in acetonitrile. The reaction mixture was stirred at room temperature for 2 
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hours. The solution was acidified (pH ~ 2), and the Fmoc- protected 7-azatryptophan was 
extracted with ethyl acetate. The combined organic layer was dried with Na2SO4 . The final 
product was obtained by removing the solvent through rotary evaporation.  
 
3. Loading Wang resin with Fmoc-D-Leu  
Wang resin loaded with Fmoc-D-Leu was used to synthesize the N-fragment.  In a 50 mL 
polypropylene centrifuge tube, 1 g (0.56 mmol) Wang resin is suspended in 15 mL of 9:1 (v/v) 
DCM/DMF mixture for 30 mins to swell. In a 20 mL glass vial, Fmoc-D-Leu (989.5 mg, 2.8 
mmol, 5 eq. relative to the resin) was dissolved in a minimum amount of DMF. HOBt (378 mg, 
2.8 mmol) was added and the mixture was stirred until HOBt is fully dissolved. Then, DIC (353 
mg, 2.8 mmol) was added to the mixture, and stirred at 0 oC for 10 mins. The mixture was 
transferred to the swelled resin. In a separate flask, 0.1 equivalents of DMAP (342 mg, 0.056 
mmol) was dissolved in a minimum amount of DMF (about 0.2 mL). The DMAP solution was 
added to the resin suspension. The mixture was shaken at room temperature for 3 hours. Then 
acetic anhydride (112 L, 1.2 mmol, 2 eq.) and pyridine (90 L, 1.2 mmol, 2 eq.) were added to 
the reaction mixture for an additional 30 mins to cap any remaining hydroxyl groups on the Wang 
resin. The resin was filterred through a medium fritted plastic funnel and washed with DMF, 
DCM and MeOH three times respectively. After the final wash, the resin was driedwith air flow 
and then high vacuo overnight.  
The loading yield was determined by measuring the absorbance of DBU-released Fmoc 
at 305 nm. 20 mg of the prepared Fmoc-D-Leu-Wang resin and commercially available Fmoc-
Gly-Wang resin (0.65 mmol/g) with known loading yield were weight into separate container. In 
the blank sample, no resin was added.  Add 2 mL of 2% DBU in DMF to the resin. When the 
Fmoc protection group is released in DBU solution, a distinct species absorbing at 305 nm is 
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formed. After 30 minutes agitation, 1 mL of the solution was diluted until the absorbance of the 
solution falls into the range 0.2 – 1.0.  The exact same dilution procedure was applied to the 
standard (Fmoc-Gly-Wang resin) and the blank (no resin).  The loading yield can be calculated by 
x/standard= (Asample-A0)/(Astandard-A0)  mstandard/msample, in which, x and standard are the loading 
yield of the Fmoc-D-Leu-Wang resin prepared above and the purchased Fmoc- Gly-Wang resin in 
mmol/g; Asample, A standard, and A0 are the absorbance of the sample, standard and blank at 305 nm; 
mstandard, msample are the mass of resin used.  The samples were prepared as triplicates and the 
average is used as the final loading yield.  
 
4. Peptide synthesis 
All peptides were synthesized using the standard Fmoc/HBTU chemistry. In general, five 
equivalents of each amino acid and 4.5 equivalents of HBTU were used for each coupling 
reaction. The 7-azatryptophan mutant was synthesized through linear synthesis. All other mutants 
were made through fragment condensation (Scheme 1-1). The first 9 amino acids (from formyl-
Val1 to Ar9, in which Ar is the chosen aromatic residue in a gA mutant) were coupled onto the 
Fmoc-D-Leu loaded Wang resin to make N-fragment. Then the resin was stirred in reagent K (80% 
TFA, 5% H2O, 2.5% EDT, 5% thioanisole and 7.5% phenol) for 2 hours at RT to cleave the N-
fragment.  The C-fragment was synthesized by coupling four amino acids (from Ar11 to D-Leu14) 
onto the Fmoc-Trp-Wang resin. Then the C-fragment was cleaved off the resin with ethanolamine 
(40% (v/v) in degassed DMF, 55oC, 5 hours). Next, the resin was filtered off through a medium 
fritted plastic funnel and rinsed three times with DCM and MeOH to release the peptide into the 
filtrate. The peptide containing filtrate was dried by rotary evaporation to a minimal volume. 
Water (6-7 times of filtrate volume) was added to precipitate both fragments from the cleavage 
cocktail. The precipitates were isolated by centrifugation (14,000 rpm, 1 hour) and the pellet was 
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dried on a lyophilizer to give two peptide fragments.  The crude material was directly used in the 
following condensation reaction. The two peptide fragments (1:1 ratio) were dissolved in 
DCM/DMF (3: 1, v/v) to make a concentration about 0.05 M.  HOAt (4 e.q.) and DIPEA (3 e.q.) 
were added to the solution and the reaction mixture was stirred at room temperature for 10 mins, 
at which point HATU (2.5 e.q.) was added. The mixture was stirred at room temperature for 
another 8-12 hours. The reaction was monitored by LC-MS until a complete conversion of 
starting material was achieved. The reaction mixture was dried by rotary evaporation to a 
minimal volume.  The final product was again precipitated by deionized water and separated from 
the supernatant by centrifugation. The pellet was then re-dissolved in MeOH and purified by 
preparative scale RP-HPLC (Waters Prep LC, Jupiter 10 m C4 300A Column). The identity and 
purity of each peptide was confirmed by analytical RP-HPLC-MS (Waters e2695, Phenomenex, 
Jupiter 5m C4 300R, ESI+) as [M]+. All peptides were confirmed to have purity of 90% or 
higher.  
The peptide gA-Ar-8L was also synthesized through fragment condensation.  Fmoc-L-
Leu-Wang resin was used to make its N-fragment of gA-Ar-8L, while the C-fragment was 
identical.  The two full-length peptides (gA-Ar-8 and gA-Ar-8L) were subjected to analytical 
HPLC (Waters e2695, Phenomenex, Jupiter 5m C4 300R) analysis and the results are presented 
in Figure 1-5.  
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Table 1-3. sequences and MS of the gA-Ar mutants discussed in chapter 1 
Name Sequence 
Calculated 
mass 
Idendified 
gA-Ar-2 
formyl-V-G-A-dL-A-dV-V-dV-f4Y-dL-f4Y-dL-
f4Y-dL-W-ethanolamine 
2031 
1016 
[M+H]2+ 
gA-Ar-3 
formyl-V-G-A-dL-A-dV-V-dV-AW-dL-AW-dL-
AW-dL-W-ethanolamine 
1890 1891 
gA-Ar-4 
formyl-V-G-A-dL-A-dV-V-dV-Y-dL-Y-dL-Y-
dL-W-ethanolamine 
1815 1816 
gA-Ar-5 
formyl-V-G-A-dL-A-dV-V-dV-F-dL-F-dL-F-dL-
W-ethanolamine 
1767 1767 
gA-Ar-6 
formyl-V-G-A-dL-A-dV-V-dV-2Pal-dL-2Pal-dL-
2Pal-dL-W-ethanolamine 
1768 1768 
gA-Ar-7 
formyl-V-G-A-dL-A-dV-V-dV-3Pal-dL-3Pal-dL-
3Pal-dL-W-ethanolamine 
1768 1768 
gA-Ar-8 
formyl-V-G-A-dL-A-dV-V-dV-4Pal-dL-4Pal-dL-
4Pal-dL-W-ethanolamine 
1768 1768 
gA-Ar-8L 
formyl-V-G-A-dL-A-dV-V-dV-4Pal-L-4Pal-dL-
4Pal-dL-W-ethanolamine 
1768 1768 
single letter codes, the D- amino acids were labelled by the italic “d”, and mutation sites are 
highlighted in bold 
 
 
III. Preparation of peptide stock solutions 
Each peptide stock solution was prepared in DMSO. The concentration was determined 
by monitoring the Trp absorbance at 280 nm. The absorbance contributed by Phe, 2Pal, 3Pal, 
4Pal, f4Y at 280 nm was negligible. Therefore, the following extinction coefficient were used in 
concentration calibration: gA-WT is 22760 cm-1M-1 (W 5690 cm-1M-1  4); gA-Ar-3 is 20930 
cm-1M-1 (W 5690 cm-1M-1 + AW 5080 cm-1M-1  3); gA-Ar-4 is 9530 cm-1M-1  (W 5690 cm-
1M-1  + Y 1280cm-1M-1 3); all other five mutants (gA-Ar-2 and gA-Ar-(5-8)) are 5690 cm-
1M-1  (W 5690 cm-1M-1 ). Then solutions with a series of dilution (2) in DMSO were made. 
Final DMSO concentration was controlled at 1% for all samples prepared for the binding and 
leakage assay.  
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IV. Size exclusion chromatography 
Peptide conformers (monomers and ds-dimers) of gA of the different mutants were 
separated and quantified by analytical HPLC through a size-exclusion column from Waters 
(Milford, MA, Ultrastyragel 1000 Å column eluted with pure THF). 17  Briefly, 10 L of a peptide 
solution dissolved in DMSO (50 M) is injected directly onto the column, releasing the 
polypeptide conformational isomers to the eluent stream. In THF, the ds-dimer and -helical 
monomer exchange extremely slowly, therefore, the results reflect the peptide conformational 
isomers in the DMSO stock solution. The flow rate was 1.0 mL/min, and the eluting peptides 
were detected with a dual-wavelength detector (280 nm and 254nm). Previous studies showed 
that gA-WT incubated in THF exists as a mixture of monomers and ds-dimer. Therefore, a 
solution of gA-WT in THF was used as a standard to determine the retention times of the 
monomers and ds-dimer under our experimental condition.   The relative amount of the 
conformational isomers is determined by the integration.  
 
V. Na+ ion leakage assay 
1. Determination of SBFI-Na+ binding constant in solution 
For the determination of SBFI-Na+ binding constant in the absence of interfering ions, 
two solutions of 5 M SBFI dissolved in A (10 mM MOPS, pH 7.0) or B (10 mM MOPS, 135 
mM NaCl, pH 7.0) were mixed in different ratios so that the mixture would have constant SBFI 
concentration and various amount of Na+. For the SBFI-Na+ binding in the presence of K+ ions, 
two solutions of 5 M SBFI dissolved in C (10 mM MOPS,135 mM KCl, pH 7.0)  and B were 
mixed in different ratio to have a solution with constant SBFI (5 M) , various amount of Na+ , 
but constant total ion concentration (135 mM Na+ and K+ together).  Then the excitation spectra 
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of these mixtures were recorded by monitoring emission at 505 nm. The intensity ratio at 340 nm 
over 380 nm was plotted against the Na+ concentration and the apparent dissociation constant was 
obtained by fitting the plot into an exponential function.   
 
2. Liposome preparation and the leakage assay 
A chloroform solution containing 76 mg POPC (POPC LUVs) was dried under reduced 
pressure to form a thin film, which was then hydrated with 2 mL aqueous buffer (10 mM MOPS, 
135 mM KCl, 20 M SBFI pH 7.0).  After 20 cycles of freezing and thawing, the liposome 
suspension was extruded 21 times through a 100 nm polycarbonate membrane (Liposofast Mini 
Extrusion system, Avanti Polar Lipids; Whatman Nuclepore Track-Etch Membrane) at RT. Free 
K+ and SBFI were removed by gel filtration (ÄKTA FPLC with HiPrepTM 16/60 Sephacryl TM-
S-500HR column) using solution B for system I and solution C for system II as the eluent.  The 
lipid concentration was determined by Stewart assay following the reported protocal38 . This 
colorimetric method is based on the complex formation between phospholipids and ammonium 
ferrothiocyanate. Briefly, 2 mL of phospholipid solution in chloroform with 2 mL of 0.1M 
NH4Fe(SCN)4 in aqueous solution was mixed and shaked for 2min.The mixture was then 
centrifuged for 5 min at 2000 rpm. The UV absorption of the chloroformsolution of the lipids was 
measured at 465 nm. The concentrations of the lipids were calculatedwith the reported extinction 
coefficient of PC 7960 M-1cm-1. Size distribution of liposomes was confirmed by Dynamic Light 
Scattering (DLS, DynaPro nanostar, Wyatt, Santa Barbara, CA). The instrument setup used the 
standard PBS parameters: refractive index @589 nm & 20○C is 1.333, viscosity is 1.019 cp, 
Cauchy coefficient is 3119 nm2. Data were acquired in auto-attenuation mode, and processed 
with DYNAMIC V6TM software. The diameters of all liposomes were found to fall into the 
narrow range of 100~150 nm with a polydispersity lower than 30% (Figure 1-16).   
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Figure 1-16. Size distribution of LUVs made of POPC determined by DLS 
 
The leakage assay with system I was performed as described below.  Various amount of 
peptide (concentration varies from 1 nM to 5 M) were mixed with POPC LUVs (500 M, LUVs 
 20 M SBFI, 10 mM MOPS, 135 mM KCl, pH 7.0) suspended in solution B. The excitation 
spectra of these mixtures were recorded by emission at 505 nm at 0 mins, 30 mins, 90 mins and 2 
hours for the first trial. The results suggested that the ion exchange reaches equilibration around 2 
hours (Figure 1-17). There are minimal changes from 90 mins and 2 hours at all concentrations 
tested. When the experiments were repeated, the mixture was incubated at room temperature for 2 
hours before the first excitation spectrum was recorded at 505 nm. The I340nm/I380 nm of each 
sample was plotted against the peptide concentration. The activity was presented as LC50 values 
(the peptide concentration required to cause about 50% of Na+ ion leakage).  The values were 
obtained by fitting the concentration profile to an exponential function.  The complete ion 
equilibration was achieved by lysing the liposome with 0.1% TritonX-100 (w/v) at the end of 
each titration experiment and 1% (v/v) DMSO addition was used as negative control. The 
I340nm/I380 nm values were normalized against both values to give the % of Na
+ equilibration.  
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Figure 1-17.  Kinetic profiles of gA-WT induced Na+ ion leakage. The graph shows relationship 
between peptide concentration and the percentage of Na+ ion leakage at 0 mins, 30 mins, 90 mins 
and 2 hours.  
 
The leakage assay with system II was performed in a similar fashion. POPC LUVs (500 
M POPC  20 M SBFI, 10 mM MOPS, 135 mM KCl, pH 7.0) was suspended in solution C , 
which has no Na+ ions. 2 hours after peptide addition, the excitation spectra were recorded. No 
excitation wavelength shift was observed. Then 135 mM NaCl was titrated into the mixture to 
generate a Na+ ion gradient across the lipids bilayer.  The systems were equilibrated for an 
additional 2 hours before the second excitation spectrums was recorded. Similarly, the I340nm/I380 
nm of each sample was normalized and plotted against the peptide concentration. The activity was 
again presented as LC50 values.  The values were obtained by fitting the concentration profile to 
an exponential function.  The complete ion equilibration was achieved by lysing the liposomes 
with 0.1% TritonX-100 (w/v) at the end of each titration. 
Channel formation of all aromatic residue modified gA mutants was tested in both system 
I and system II.  Similar LC50 values were obtained. Figure 1-11 shows the values obtained in 
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system I. For reasons unknown, the absolute fluorescence intensity in system II decreases when 
peptide concentration is higher than 250 nM after 4 hours of incubation. Similar LC50 values in 
system II were obtained when data from the low peptide concentration were fitted.  
 
VI. The determination of peptide binding 
20 mg of POPC was dissolved in 2 mL of chloroform and dried under high vacuum to 
form a thin layer. Then the lipids were hydrated with 5 mL of buffer solution B (10 mM MOPS, 
135 mM NaCl, pH 7.0) by ultrasonication as described in the Avanti Polar Lipids protocol. Small 
unilamellar vesicles (SUVs) form during the process. After the solution becomes transparent 
(normally takes about 20 mins), it was filtered through 0.2 m syringe filter to remove possible 
aggregates and a small amount of metal tip leaked from the ultrasonication probe. SUVs were 
chosen over LUVs to minimize the light scattering effect and presumably the error in the 
measurement. Similar Kd values but with much bigger error were obtained with both SUVs and 
LUVs for gA-Ar-2 (SUVs: 234, LUVs: 229). 
Peptide binding was monitored by the fluorescence shift of the Trp emission maximum 
upon binding to hydrophobic liposomes or the fluorescence enhancement of 7-azatryptophan 
upon binding. The gA mutants (1 M) were mixed with various amounts of SUVs in solution B.  
The mixture was agitated gently for 30 mins before the fluorescence spectra of Trp or 7-
azatryptophan were scanned between 320 nm and 400 nm (ex = 280 nm) on a SpectraMax M5 
(Molecular Devices, Sunnyvale, CA). For gA-Ar-3 the intensity at 380 nm was plotted against 
the L/P ratios. And for the rest of gA mutants, the ratio of fluorescence intensity at 330 nm and 
350 nm (I330nm/I350nm) was calculated and plotted against the L/P ratios. Then binding curve was 
fitted into an exponential function to obtain an apparent dissociation constant ( value, Figure 1-
13).  
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VII. Tb3+  ion leakage assay 
A chloroform solution containing 76 mg of POPC (POPC LUVs) was dried under 
reduced pressure to form a thin film, which was then hydrated with 2 mL aqueous buffer (10 mM 
TES, 100 mM sodium citrate, 50 mM TbCl3 , pH 7.0).  After 20 cycles of freezing and thawing, 
the liposome suspension was extruded 21 times through a 100 nm polycarbonate membrane 
(Liposofast Mini Extrusion system, Avanti Polar Lipids; Whatman Nuclepore Track-Etch 
Membrane) at RT. The external solution was removed by gel filtration using 10 mM TES, 100 
mM sodium citrate, pH 7.0 as eluent. The leakage of Tb3+ from liposomes was monitored by the 
luminescence of the Tb/DPA complex. To a mixture of LUVs (500 M, POPC 10 mM TES, 
100 mM sodium citrate, 50 mM TbCl3 , pH 7.0) and DPA (50 M) in  buffer (10 mM TES, 100 
mM sodium citrate, pH 7.0), peptide was added (the amount of DMSO was controlled to less than 
1%). The peptide liposome mixture was incubated at RT for 30 mins before the fluorescence 
intensity of the Tb/DPA complex (ex=270nm, em=490 nm) was recorded (Ic) in a quartz cuvette 
on a MicroMax 384 fluorescence spectrometer (Jobin Yvon, Horiba Scientific).39  Complete Tb3+ 
leakage was assessed by TritonX-100 lysing of liposomes (If). A sample with pure DMSO 
addition was used as blank (I0) and the fraction of Tb
3+ leakage was calculated as fraction = (Ic-
I0)/(If-I0) .  
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Chapter 2. Towards Bacterium Specific Ion Channels: Solublized Gramicidin A as 
Potential Systemic Antibiotics   
2.1 Introduction 
2.1.1 Antibiotic resistance 
Bacterial infections cause a high morbidity and mortality and serious problems in public 
health. Since the introduction of the first effective antibiotics, namely the sulfonamide-based 
antibiotics, followed by the golden age of antibiotic development (1950-1980), antibiotics were 
considered as a panacea to cure infections (Figure 2-1).1  Unfortunately, the success of new 
antibiotics was later found to be compromised by the fast development of resistance. Antibiotic 
resistance was identified since the 1960s (Figure 2-1). While the number of resistant bacterial 
strains continues to increase at an alarming rate, new antibiotic production is actually slowing 
down (Figure 2-2).2 ,3  Traditional antibiotics bind to specific receptors and inhibit crucial 
processes such as cell wall synthesis, protein synthesis, and DNA replication. It is surprisingly 
easy for bacteria to generate resistance through a variety of mechanisms (Table 2-1). 1 ,4  An ever 
evolving pipeline of antibiotics is required for modern medicine to remain one step ahead of 
pathogens. The main challenge of developing a new antibiotic is the identification of new targets 
as well as molecules that inhibit that target. Because targeting certain receptors or enzymes likely 
leads to resistance development in a short period of time, antibiotics that function through a 
different mechanism are desirable. Membrane targeting peptides are considered as new and 
attractive candidates of antibiotics in the future.5  In recent years, a significant amount of effort 
has been put into developing membrane-active peptides and their functional analogous as novel 
antibiotics.6 ,7  
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Figure 2-1. History of antibiotic discovery and concomitant development of antibiotic resistance. 
Graph is reconstructed from reference 1. 
 
Table 2-1. Modes of action and resistance mechanisms of commonly used antibiotics 
Antibiotic class Example(s) Target Mode(s) of resistance 
-Lactams Penicillins (ampicillin) 
Peptidoglycan 
biosynthesis 
Hydrolysis,efflux, altered 
target 
Aminoglycosides 
Gentamicin,streptomycin, 
spectinomycin 
Translation 
Phosphorylation, acetylation, 
nucleotidylation,efflux, altered 
target 
Glycopeptides Vancomycin, teicoplanin 
Peptidoglycan 
biosynthesis 
Reprogramming peptidoglycan 
biosynthesis 
Tetracyclines Minocycline, tigecycline Translation 
Monooxygenation, efflux, 
altered target 
Sulfonamides Sulfamethoxazole C1 metabolism Efflux, altered target 
Quinolones Ciprofloxacin 
DNA 
replication 
Acetylation, efflux, altered 
target 
Streptogramins Synercid Translation 
C-O lyase (type B 
streptogramins), 
acetylation (type A 
streptogramins), 
efflux, altered target 
Macrolides 
Erythromycin, 
azithromicin 
Translation 
Hydrolysis, glycosylation, 
phosphorylation, 
efflux, altered target 
47 
 
 
 
Figure 2-2: a) Trends of antibiotic resistance, y-axis represents the growing proportions of 
ciproﬂoxacin resistance b) Trends of new antibiotic production in the past two decades. The x-
axis represents the time. Graphs are reconstructed from references 4 and 5. 
 
2.1.2 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are a family of short peptides (12-80 amino acids) that 
function as broad-spectrum antimicrobial agents and serve as the frontline to combat bacteria, 
protozoa and other microbial agents.8 ,9  As a class, AMPs are loosely defined. The only shared 
property is their prototypical function in killing bacteria. AMPs include a variety of primary and 
secondary structures.10   Despite other mechanisms proposed recently, they are generally believed 
to work by directly perturbing the plasma membrane.11 ,12 ,13  Multiple models have been proposed 
to explain AMPs mechanism of action. The three most prominent models are the carpet model, 
the barrel-stave model, and the toroidal pore model (Figure 2-3).11  In the carpet model, the 
peptides disrupt the membrane by orienting parallel to the surface of the lipid bilayer and forming 
an extensive layer or carpet. In the barrel-stave model, the attached peptides aggregate and insert 
into the membrane bilayer so that the hydrophobic peptide regions align with the lipid core region 
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and the hydrophilic peptide regions form the interior region of the pore. In the toroidal model, the 
attached peptides aggregate and induce the lipid monolayers to bend continuously through the 
pore so that the water core is lined by both the inserted peptides and the lipid head groups. 
However the actual mechanism may follow a mix of these three and there are no selectivity on 
the leakage of internal contents.  
To survive, a cell must have an intact plasma membrane that functions as a barrier to 
separate the interior contents from the outside environment, and controls the transport of polar 
molecules. Proper cell function and viability rely on membrane integrity and a normal ion 
gradient across the membrane. When AMPs disrupt the membrane integrity, cellular metabolism 
is interrupted and cells are killed.  
 
 
Figure 2-3.  Proposed mechanisms of AMP induced killing. a) the carpet model; b) the barrel 
stave model; and c) the toroidal pore model. Graphs are reconstructed from reference 11. 
 
Different cell types have distinct membrane composition.7 ,14 ,15 The plasma membrane of 
mammalian cells consists of about 60% of phospholipids and 25% of cholesterol with an 
49 
 
asymmetric distribution of phospholipids between the outer and inner leaflets of the bilayer, 
exposing the zwitterionic phosphatidylcholine (PC) and sphingomyelin (SM) to the extracellular 
side.15  In contrast, both Gram-positive and Gram-negative membranes consist of a large fraction 
of negatively charged lipids such as phosphatidylglycerol (PG) and diphosphatidylglycerol or 
cardiolipin (CL) and the zwitterionic phosphatidylethanolamine (PE). This is the primary reason 
that most AMPs have a net positive charge. Due to the charge-charge attraction, AMPs 
preferentially bind and disrupt the microbial (negatively charged) rather than the eukaryotic 
(neutral) membranes.  The characteristic lipid composition described above for a given cell 
membrane results from millions of years of evolution. Modification of the lipid composition and 
distribution is considered to be highly costly for bacteria. Therefore, AMPs are expected to have a 
longer effective lifetime before the rise of resistance. However, rational improvement of naturally 
occurring AMPs or synthetic membrane toxins into systemic antibiotics has been difficult due to 
the lack of detailed mechanistic understandings.   
 
2.1.3 Gramicidin A as an antibiotic 
The structure and mechanism of gA as a transmembrane channel have been described in 
chapter 1.16  gA is not only considered as a model membrane channel, but also has been used as 
an ingredient in the commercialized antibiotic ointment polysporin in Canada.  As described, gA 
binds onto a membrane lipid bilayer and forms channels that allow monovalent ions to diffuse 
through. When gA forms a channel on the cell membrane, it disrupts the essential ion gradient 
and consequently causes cell death. In contrast to the majority of AMPs, gA has a clearly defined 
structure and mechanism of membrane lysis. Thus rational optimization of its properties is 
feasible. As one can tell from its primary sequence, gA is essentially insoluble in water (< 50 nM) 
and induces hemolysis under the concentrations required to cause bacterial cell death (vide infra). 
As a result, its therapeutic usage has been limited to topical applications. 17 ,18  
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Herein, I will introduce my research on developing a solubilized gA that no longer 
suffers from the problems mentioned above but retains membrane channel activity, holding great 
promise as a systemic antibiotic. There are several reasons for us to choose gA as the starting 
point for further engineering and optimization. First, gA has been used as an antibiotic. Its 
efficacy as an antibiotic has been confirmed.  Second, gA is composed of alternating D- and L- 
amino acids and is both N-terminal (formyl) and C-terminal (ethanolamine) protected.  Therefore, 
the peptide is more resistant to protease degradation.19  Third, gA has well defined structure and 
mechanism of action. Finally, gA functions as a monovalent ion channel. For mammalian cells, 
monovalent ion channels have been reported to play an important role in controlled cell death.20  
We hope that bacterium death caused by gA would go through a similar controlled cell death 
pathway. Thus it is less likely to trigger a serious immune response compared other AMPs, which 
release cytosolic material instantly through a detergent type mechanism. Our peptide design was 
inspired by natural cationic AMPs, and the experimental results have shown that gA mutants 
carrying multiple positive charges (e.g. D-Lys residues) are highly soluble in aqueous solution. 
These peptides are shown to inhibit bacterium growth at a concentration much lower than that 
needed to cause hemoglobin leakage from human red blood cells (hRBCs), yielding a greater 
therapeutic window.  Furthermore, modification on the Lys side chains allows one to fine tune the 
antimicrobial activities of these gA mutants.  
 
2.2 Design and characterization of solubilized gA  
As mentioned above, bacterial cell membranes consist of a large fraction of negatively 
charged lipids, and therefore display a greater affinity for cationic peptides. Inspired by this, we 
hypothesize that strategic incorporation of cationic residues into gA will afford specific bacterial 
toxicity if the mutants retain the channel-forming structure and function. In addition, the charged 
residues will greatly improve the water solubility.  
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2.2.1 Synthesis and structure analysis of the gA mutants 
The structure of gA in a lipid bilayer  was determined by solid state NMR in 1996.21  A 
close examination of the dimeric channel structure reveals that the D-Leu residues at positions 10, 
12 and 14 are ideal for mutation because they are located at the membrane-water interface, where 
charged side chains can be best accommodated without altering the channel structure (Figure 2-4). 
More specifically, the distance between the α-carbon of the residues at position 10 to the tail of 
gA is about 15 Å, which is similar to the length of four carbon-carbon bonds.  Among the twenty 
natural amino acids, both Lys and Arg have a proper side chain length that would allow the 
positive charge carried by these residues to locate at the aqueous environment without altering the 
channel structure. As the number of charged residues would affect water solubility and selective 
membrane association of gA mutants, we first varied the number and the position of the charged 
residues by replacing one or multiple D-Leu with D-Lys to achieve an optimized combination 
(Table 2-2). Given the high abundance of Arg residues in natural antimicrobial peptides, we 
would also tested gA muant with D-Arg residues in the best combination.  
 
 
 
 
 
 
Figure 2-4.  Mechanism of gA channel formation in a lipid bilayer and a detailed structure 
analysis. The distance between the α-carbon at position 10 and the peptide tail, and the distance 
changes with positions 10 and 12 are labeled respectively. The D-Leu residues are highlighted in 
orange and the gA peptide sequences are shown in the bottom in which the D- amino acids are 
marked by italic “d”. 
formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dL-W-NHCH2CH2OH  
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All peptides were synthesized through solid phase peptide synthesis using the standard 
Fmoc/HBTU chemistry (see experimental procedures). The formyl-Val was incorporated into the 
peptide as a building block.22  After peptide elongation on Wang resin, the gA mutants were 
cleaved off from the resin with 40% ethanolamine in DMF, and precipitated with water to give 
the gA mutants with Boc- protected D-Lys. Then the Boc- protecting groups were removed by 
TFA treatment. The final product was precipitated from the cleavage cocktail by diethyl ether and 
purified by preparative scale RP-HPLC. The incorporation of D-Lys into the gA sequence made 
the peptides much easier to synthesize and purify. All peptides were characterized by LC-MS for 
purity (> 95%) and integrity (Table 2-2 and Table 2-10).  
 
Table 2-2.  Sequences of the gA mutants used in this section 
Peptide Sequences[a] 
gA-WT      formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dL-W-NHCH2CH2OH 
gA-1 formyl-V-G-A-dL-A-dV-V-dV-W-dK-W-dL-W-dL-W-NHCH2CH2OH 
gA-2 formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dK-W-NHCH2CH2OH 
gA-3 formyl-V-G-A-dL-A-dV-V-dV-W-dK-W-dL-W-dK-W-NHCH2CH2OH 
gA-4 formyl-V-G-A-dL-A-dV-V-dV-W-dK-W-dK-W-dL-W-NHCH2CH2OH 
gA-5 formyl-V-G-A-dL-A-dV-V-dV-W-dK-W-dK-W-dK-W-NHCH2CH2OH 
gA-6 formyl-V-G-A-dL-A-dV-V-dV-W-dR-W-dR-W-dR-W-NHCH2CH2OH 
[a] single letter codes, the D- amino acids were labelled by the italic “d”, and mutation sites 
are highlighted in bold 
 
2.2.2 In vitro characterization of the solubilized gA 
To test our hypothesis, we first determined the peptides’ solubility in aqueous buffer (10 
mM HEPES, pH 7.0 with 1% of DMSO). As expected, the D-Lys incorporation dramatically 
improves the water solubility of gA mutants. Under our experiment conditions, gA-WT is not 
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detectable by Trp absorption. In contrast, our gA mutants carrying various numbers of charges 
display the characteristic Trp absorption in aqueous solution with no indication of aggregation 
(Figure 2-5). Peptide solubility increases with the number of D-Lys residues and does not depend 
on their positions. The triple D-Lys peptide (gA-5) is readily soluble at concentrations close to 
100 M. The solubility is better than that of the wild type by three orders of magnitude.  
 
 
Figure 2-5. Water solubility of the gA variants is determined by Trp absorbance at 280 nm. 
Representative  Trp absorption spectra of gA-WT and gA-5 and solubility of gA mutants are 
listed in the table. [a] The solubility of gA-WT was obtained from reference 22. 
 
To further understand the distribution of these D-Lys containing gA mutants in a cell 
suspension solution, we measured the binding affinities of the gA mutants to membranes of 
different compositions. LUVs (~100 nm in diameter) made of POPC were used as a mimic of 
mammalian cells, while vesicles composed of POPC/POPG (1:1; 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) were prepared to 
represent bacterial membranes. The peptide-vesicle association was evaluated via a titration 
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experiment, in which LUVs were titrated into peptide solutions, and the spectral shift of Trp 
fluorescence was recorded. Fitting the titration curves yielded the apparent dissociation constants 
(Kd) that are presented in lipid/peptide ratios (Figure 2-6, Figure 2-28). The single D-Lys mutants, 
gA-1 and gA-2 display no discrimination against neutral and negative membranes, yielding 
apparent Kd values close to that of the gA-WT. In contrast, the double D-Lys variants gA-3 and 
gA-4 exhibit a much reduced affinity (by ~ 70 fold) to POPC vesicles, while their affinity to 
POPC/POPG vesicles remains comparable to that of gA-WT. Therefore, these two gA mutants 
display a minor selectivity on the lipid composition of vesicles. Under the same experimental 
conditions, the triple D-Lys mutant gA-5 shows no detectable binding to the neutral POPC 
vesicles (up to L/P = 2,000), while its Kd value toward the negatively charged membrane dropped 
by a marginal four folds compared to the wild-type. The membrane selectivity of the triple D-Arg 
mutant gA-6, however, is minor. It binds much tighter with the neutral vesicles compared to gA-5.  
In general, the cationic gA-x mutants are less hydrophobic, and therefore less likely to binds with 
neutral POPC liposomes. Peptide associations with negative POPC/POPG vesicles were 
promoted by the Coulombic attraction. As a result, gA mutants with cationic residues show 
membrane selective association. Their promise as novel systemic antibiotics ultimately relies on 
their ability to cause ion gradient equilibration by forming effective channels in the lipid bilayer.  
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Figure 2-6. Apparent dissociation constants (Kd) of the gA mutants presented as lipid/peptide 
(L/P) ratios.  
 
We then tested the channel activities of these gA mutants by a K+ ion leakage assay. K+ 
ions were encapsulated in neutral (POPC only) or negatively charged (POPC/POPG = 1:1) 
vesicles with the same amount of Na+ ions in the outside buffer to balance the osmotic pressure. 
Upon channel formation, driven by the ion gradient, K+ ions diffuse out across the lipid bilayer 
through the channel and are detected by a potassium ion selective electrode (K-ISE). DMSO 
addition was used as negative control, while 10 M gA-WT was added to achieve 100% ion 
equilibration. Similar to the binding results, we observed a selective activity on the negative 
charged vesicles by the cationic gA mutant but not the gA-WT(Figure 2-7). gA mutants carrying 
multiple D-Lys residues readily induce K+ ion leakage from the negatively POPC/POPG LUVS, 
which contrast sharply to the neutral liposomes (POPC LUVs).  
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Figure 2-7. Ion leakage profile of gA mutants a) The concentration profile of gA-WT induced K+ 
leakage from the negative (POPC/PCPG) and neutral (POPC) vesicles. b) The concentration 
profile of gA-5 induced K+ leakage from the negative (POPC/PCPG) and neutral (POPC) vesicles. 
K+ ion concentrations were detected by voltage changes of K-ISE. 
 
With the D-Lys residues incorporated towards the C-terminus, the gA mutants described 
above display amphipathic sequences. Since many amphipathic peptides are known to cause 
membrane damage through a detergent-like mechanism,23  we further examined whether it is the 
case with the gA mutants studied here. As described earlier, while the K+ ions are small enough, 
Tb3+ ions are too big to diffuse through if the gA mutants form a similar channel as the gA-WT. 
(Figure 2-8). Otherwise, a similar leakage profile would be observed for both ions. Toward this 
end, we assessed the mutants’ conformation with an ion selectivity assay by comparing the 
efficacy of gA mutants in inducing ion leakage from liposomes encapsulating K+ and Tb3+ 
respectively.  
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Figure 2-8. gA mutants (500 nM) induced Tb3+ ion leakage from LUVs (500 M, POPC or 
POPC/POPG) determined by luminescence spectra of the Tb3+/DPA complex. DMSO addition 
was used as negative control and complete ion release is induced by 0.1% TritonX-100. The 
insert graph: a schematic representation of the relative size of K+ ion, gA channel and Tb3+ ion. 
 
For all gA mutants, essentially no Tb3+ leakage was observed at a peptide concentration 
five times of that required for complete K+ ion release from the LUVs (Figure 2-7, Figure 2-8). 
This indicates that these gA mutants fold into the wild type like structures, which selectively 
transport monovalent cations. The wild type like channel structure of the D-Lys mutants is further 
supported by the fact that gA-5 and gA-WT share similar signatures in their circular dichroism 
spectra (CD spectra, Figure 2-9). This exclusive leakage of monovalent cations is supportive to 
our hypothesis that cationic residues incorporated at the C-terminus can be well accommodated 
without altering the channel structure.  
Indeed, the results of in vitro characterization are consistent with our hypothesis about the 
designed gA mutants. Their potential as systemic antibiotics was tested with cell based assays.  
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Figure 2-9. CD spectra of gA-WT and gA-5 in (A) DPC or (B) SDS micelles at 1: 50 gA: lipid 
ratio. (The spectra shown are the averaged signal of three scans after subtracting the DPC or SDS 
micelle signal). 
 
2.2.3 Cell based antimicrobial activity and toxicity evaluation 
The antimicrobial activity of the gA mutants was evaluated on four bacterial strains and 
the results were compared to the wild type gA (Table 2-3). The bacterial strains tested included 
the Gram-negative E. coli (BL 21), and Gram-positive B. subtilis (ATCC 663), S. aureus (ATCC 
6538) and S. pyogenes (ATCC 19615). The minimum inhibitory concentration (MIC) was 
determined by a standard microdilution procedure.24  Consistent with the previous reports, none of 
the peptides, including gA-WT, effectively kills the Gram-negative E. coli.25 ,26  In sharp contrast, 
potent antimicrobial activity was observed against all three strains of Gram-positive bacteria, with 
MIC values ranging from high nM to low M. To kill a bacterium, gA peptides need to form 
channels on bacterial cytoplasmic membrane. The peptides could be trapped into the outer 
membrane of Gram-negative E. coli, on which channel formation does not affect the membrane 
potential of the bacterium. For Gram-positive bacteria, the peptides can directly function on 
cytoplamic membrane. Interestingly, all gA mutants except gA-5 display MIC values essentially 
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identical to that of gA-WT, indicating the charged residues do not compromise the channel 
forming potential of gA in bacterial membranes. A reduced potency against S. aureus was 
observed for the triple D-Lys mutant gA-5, with a MIC value greater than 10 M. However, it 
remains highly potent against B. subtilis and S. pyogenes. The antimicrobial potency of the gA 
mutants parallels the best antimicrobial peptides reported to date (low M).27 ,28  
As a preliminary evaluation of the peptides’ toxicities, we measured their membrane 
activity against hRBCs (Table 2-3) through two complementary approaches. The typical 
hemolytic assay29  monitors leakage of hemoglobin as a consequence of peptide-induced 
membrane damage. In addition, we also specifically evaluated peptide-induced K+ leakage from 
the red blood cells by using atomic emission spectroscopy (AES)30 , in which K+ concentration 
released can be assessed by its characteristic emission at 766.5 nm. The results show that gA-WT 
is highly efficient in inserting into hRBC membranes to give transmembrane channels. 50% of 
intracellular K+ ion leakage was observed at a peptide concentration of only 140 pM (KC50, 140 
pM). gA-WT causes hemoglobin release from hRBCs at a concentration similar to that of MIC 
(MIC, 2.5 M and HC50, 5 M), consistent with the known fact that gA-WT lacks membrane 
selectivity and is therefore highly toxic. Importantly, there is a concentration gap for the gA-
triggered K+ leakage and hemoglobin release, indicating that gA-WT predominantly forms K+ 
specific channels at low concentrations (< 5 M). 
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Table 2-3. Antibacterial activity and preliminary toxicity against hRBCS of gA-x. 
 
MICs [a][b] / M   
B. subtilis S. aureus S. pyogenes HC50 
[c] KC50 
[d] 
gA-WT 2.5 2.5 0.16 5 1.40E-4 
gA-1 5 2.5 0.16 5 ~ 10 0.01 
gA-2 5 2.5 0.16 5 ~ 10 0.01 
gA-3 5 5 0.32 > 70 5 ~ 10 
gA-4 2.5 5 0.32 > 100 5 ~ 10 
gA-5 5 >10[e] 0.16 > 100 > 100 
gA-6 2.5 ~5 >10[e] 0.62 20 0.16 
[a] MIC is the minimum inhibition concentration determined by a standard micro-dilution 
procedure.24  [b] None of the peptides tested was active against E. coli at a concentration up to 
100 M. [c] HC50 is the peptide concentration required to cause 50% of the haemoglobin leakage 
relative to cell lysis by 1% TritonX-100. For gA-3/4 the highest concentration tested are not 
enough to cause 50% haemoglobin leakage. And for gA-5 there is no noticeable haemoglobin 
leakage at 100 M. [d] KC50 is the peptide concentration required to cause 50% K
+ Ion leakage 
relative to the cell lysis by 1% TritonX-100; gA-5 does not cause noticeable K+ ion leakage from 
the hRBCs at the highest concentration tested 100 M. nd stands for not determined [e] gA-5/6 
do not show complete inhibition of S. aureus growth at the concentration range tested, and the 
IC50 for both peptides against S. aureus are 2.5 -5 M. 
 
As we anticipated, D-Lys incorporation reduces the membrane lytic potency of gA 
towards hRBCs. The KC50 values correlate well with the number of Lys residues incorporated: 
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the single Lys mutants display KC50 values higher by ~ 100 folds than that of gA-WT. Again the 
channel-forming potential appears to be independent of the position of the D-Lys residue. 
Addition of the second D-Lys residue reduces the peptides’ ability to induce K+ leakage by 
another three orders of magnitude to give KC50 values of ~ 10 M. For the triple D-Lys mutant 
gA-5, no K+ leakage is observed even at concentrations as high as 100 M. Similarly, the 
peptide-induced hemoglobin release requires gA mutants at higher concentrations as well. While 
the single D-Lys mutants display hemolytic potency comparable to gA-WT, the double mutants 
afford significantly higher HC50 values (>70 M). Again the triple D-Lys gA-5 induces no 
detectable hemoglobin release at the concentrations tested. These results demonstrate that 
introducing D-Lys residues effectively eliminates gA toxicity towards hRBCs.  
 
 
Figure 2-10.  Distinct toxicity profiles of gA-WT and gA-5 against two human cancer cell lines 
(HeLa and MCF-7), demonstrating D-Lys incorporation abolishes gA’s toxicity against 
mammalian cells. 
We further examined the toxicity of the gA mutants against two commonly used human 
cancer cell lines (HeLa and MCF-7). Specifically we measured the percentages of cell survival 
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under varied peptide concentrations through the MTT assay.31  Similar to the results for hRBCs, 
gA-WT effectively kills both types of cells with low M potency. In sharp contrast, cell growth 
is essentially unaffected by the triple D-Lys mutant gA-5 (Figure 2-10).   Comparison of the 
bacterial and mammalian cell toxicity data reveals a remarkable therapeutic window (at least 
three orders of magnitude in concentration) for gA-5, which parallels the best amphipathic 
antimicrobial peptides reported to date.27 ,28    
A full characterization of D-Lys modified gA mutants suggested the triple modification 
had the most optimized properties. We then prepared and evaluated the gA mutant (gA-6) 
substituting the three D-Lys in gA-5 with three D-Arg residues. Compared to gA-WT, gA-6 also 
has increased water solubility (Figure 2-5) and membrane selectivity (Figure 2-6). It also forms 
an ion specific channel on liposomes. While gA-6 keeps low M potency against bacterial cells, 
it displays hemolytic activity with an HC50 value of 20 M, which is less favourable than the gA 
mutants with two or three D-Lys residues (Table 2-3). The higher hemolytic activity is 
presumably because arginine, in comparison to Lys, better facilitates the peptide partitioning into 
mammalian cell membranes.32 ,33  
 
2.2.4 Summary 
In summary, we have successfully converted the nonselective channel-forming toxin gA 
into a bacterium-specific ion channel. Our best candidate gA-5 is highly potent against Gram-
positive bacteria, yet nontoxic toward at least three mammalian cell lines (hRBCs, HeLa and 
MCF-7). Our design strategy introduces cationic residues into the gA sequence in order to 
increase the aqueous solubility and to target the negatively charged membranes of bacteria. Based 
on the detailed structure and mechanism analysis, the charged residues are strategically placed 
towards the C-terminus of gA, where they appear to be easily accommodated without 
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compromising gA channel formation. The gA mutants discussed above are novel because they 
form well-defined channels only permeable to water and monovalent cations, while most of 
amphipathic AMPs cause nonspecific membrane damage whose mechanism remains largely 
unknown. The well defined mechanism of action, in addition to the remarkable bacteria-
selectivity, makes these gA mutants highly promising as the novel systemic antibiotics. And this 
strategy has potential to be expanded through engineering of other peptides.  
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2.3 Lys side chain modifications of the solubilized gA  
2.3.1 Hydrophobicity and antimicrobial peptides 
The structure and activity relationship of cationic AMPs has been heavily studied in the 
past decade. AMPs are believed to function by disrupting the plasma membrane of bacterial 
cells.11 ,12 ,13  From a therapeutic point of view, the ideal antimicrobial peptide should rupture the 
bacterial membrane without disturbing the mammalian cell membrane.  From a mechanistic point 
of view, high membrane absorption is prerequisite for potent membrane disruption. In addition to 
the net positive charges that drive the bacterial membrane association through charge-charge 
attraction. The hydrophobicity also plays an important role in peptide-membrane interactions. In 
general, increased hydrophobicity promotes the membrane association and boosts the 
antimicrobial activity. 34 ,35 Accordingly, we hypothesized that increasing the hydrophobicity of  
the Lys containing gA mutants while keeping the positive charges would selectively increase the 
antibacterial activity but not mammalian cell toxicity. 
Lys N-methylation recently received attention for its role in regulating the transcriptional 
status of chromatin through the histone proteins.36 ,37  In contrast, few references are available 
about the effect of Lys methylation in the AMP field. It is well known that Lys N-trimethylation 
increases the hydrophobicity while keeping the same net charge as Lys at physiological pH. A 
simple Spartan calculation showed consistent results. The desolvation energy of 
tetramethylammonium is 100kJ/mol less than that of methylammonium (CH3CH2-N(CH3)3
+: -
200.09 kJ/mol and CH3CH2-NH3
+: -313.52 kJ/mol). Therefore, lysine N-trimethylation could be 
a useful way to adjust the hydrophobicity of gA mutants and to keep the positive charge, 
consequently, tuning the antimicrobial activity of gA mutants. In this section, I will discuss the 
effect of Lys N-trimethylation on gA Lys containing mutants.  
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2.3.2 Synthesis and characterization of gA mutants with Lys N-trimethylation 
Synthesis and characterization of gA mutants with Lys N-trimethylation was easily 
achieved in high yield and purity (Table 2-10) by mixing the lysine containing gA mutants (Table 
2-2) with methyl iodide in large excess at high temperature. The peptide was named accordingly 
(Table 2-4, in the following contents, the gA mutants with Lys are named as gA-x, and the gA 
mutants with N-trimethylation Lys are named as gA-xM, in which x is the number of each gA 
mutant). 
 
Table 2-4. Sequences of the Lys N-trimethylated gA mutants 
Peptide Sequences[a] 
gA-WT formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dL-W-NHCH2CH2OH 
gA-1M formyl-V-G-A-dL-A-dV-V-dV-W-dMe3K-W-dL-W-dL-W-NHCH2CH2OH 
gA-2M formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W- dMe3K -W-NHCH2CH2OH 
gA-3M formyl-V-G-A-dL-A-dV-V-dV-W- dMe3K -W-dL-W- dMe3K -W-NHCH2CH2OH 
gA-4M formyl-V-G-A-dL-A-dV-V-dV-W- dMe3K -W- dMe3K -W-dL-W-NHCH2CH2OH 
gA-5M formyl-V-G-A-dL-A-dV-V-dV-W- dMe3K -W- dMe3K -W- dMe3K -W-NHCH2CH2OH 
[a] single letter codes, the D- amino acids are labelled by the italic “d”, and mutation sites are 
highlighted in bold.  
 
To evaluate the relative hydrophobicity, the gA mutants were subjected to RP-HPLC 
analysis, in which the retention time reflects peptide hydrophobicity. On a reverse phase column, 
the longer the retention time is, the more hydrophobic the peptide.38 ,39 Unfortunately, the 
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retention time differences before and after N-trimethylation were too small to gain insight into 
the hydrophobicity of gA mutants (Table 2-5). When peptides solubility were evaluated,  gA-xM  
mutants showed decreased solubility compared to the corresponding gA-x mutants, suggesting 
that Lys N-trimethylation indeed increases the peptide hydrophobicity(Table 2-5).   
 
Table 2-5. Hydrophobicity and solubility comparison of gA mutants containing N-trimethylated 
Lys and Lys 
Peptide  
C4 column retention 
time/min [a] 
Solubility/ M [b] 
gA-1M  26.8  4.3 
gA-1  27.0  10 
gA-2M  26.5  3.6 
gA-2  26.4  11 
gA-3M  24.9  30 
gA-3  24.9 38 
gA-4M 24.9 
27 
gA-4 24. 8 
39 
gA-5M 22.9 
55 
gA-5 22.9 
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A peptide solution in DMSO was injected on C4 RP-HPLC column and eluted with linear 
gradient (5 % -95% buffer B over 20 min, in which buffer A is 5% CH3CN, 95% water and 0.1% 
TFA; buffer B is 95% CH3CN, 5% water and 0.1% TFA 
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The antimicrobial activities were first tested using the same micro-dilution procedures 
(section 2.2) against four bacterial strains: the Gram-negative E. coli (BL 21), and Gram-positives 
B. subtilis (ATCC 663), S. aureus (ATCC 6538) and S. pyogenes (ATCC 19615). Consistent with 
other gA mutants, none of the peptides show activity against the Gram-negative E. coli (data not 
shown). However, most mutants showed decreased antimicrobial activity against the Gram-
positive strains compared to the Lys version (Table 2-3, Table2-6, Figure 2-11, Figure 2-12). 
Despite the fact that Lys N-trimethylation increased peptide hydrophobicity; it failed to boost its 
antibacterial activity as we had proposed. Especially, the gA-5M fails to kill bacteria at 
concentration up to 80 M; it lost its antibacterial activity against the three Gram-positive 
bacterial strains we tested. The gA-4M mutant lost its activity against two of the three Gram-
positive strains tested (Table 2-6).  
Similarly, the toxicities were evaluated on human red blood cells through two 
complementary assays: (1) the typical hemolytic assay monitors leakage of haemoglobin as a 
consequence of peptide-induced membrane damage; (2) the peptide-induced K+ leakage assay 
monitors the ion channel formation on hRBCs membrane under identical conditions (Table 2-6). 
The results combined together suggested that gA-(1-2)M reduced toxicities to a larger extent than 
antibiotic activities (Table 2-6). The peptides containing more than one N-trimethylated Lys 
(gA-(3-5) M) showed little hemolytic activity against hRBCs at the concentrations tested. We 
were only able to comparatively quantify this change in activities and the toxicities of the single 
modified mutants (gA-1M, gA-2M), as the HC50 values gA-(3-5)M are out of tested range. A 
moderate gain (2-7 folds, Table 2-7) in therapeutic index40  was observed. In general, Lys N-
trimethylation decreases the activities of gA mutants in a membrane dependent manner. And to 
our benefit as potential systemic antibiotics, the loss of activity against the neutral mammalian 
cell is more important.   
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Table 2-6. Antimicrobial activities and toxicities against hRBCs of the gA-xM mutants 
Peptide Minimum Inhibition Concentration (MIC) / 
M[a] 
Toxicity/ M 
B. subtilis S. aureus S. pyogenes HC50
[c] KC50
[d] 
gA-WT 2.5 2.5 0.16 5 0.00014 
gA-1M 2.5 2.5 0.15 19 0.04 
gA-2M 2.5 1.25-2.5 0.078 24 
0.015 
 
gA-3M 2.5 15 1.25 >24 20 
gA-4M na (15)[b] na (15) 15 >10 >10 
gA-5M 
>80  
(80% killing)[e] 
na (80) 
> 80  
(90% killing) 
>95 >95 
[a] The minimum inhibition concentration is determined by the standard micro-dilution methods, 
all tests were repeated at least three times to confirm the reproducibility. None of the peptides 
tested was active against the Gram-negative E. coli (data not shown). [b] na (concentration) 
means that no noticeable bacteria growth inhibition were observed up the concentration labelled 
in the parentheses. [c] HC50 is the peptide concentration required to cause 50% of haemoglobin 
leakage from human red blood cells (hRBCs) compared to the complete lysis of same amount 
cells by 1% TritonX-100. [d] KC50 is the peptide concentration required to cause 50% K
+ ion 
leakage from human red blood cells relative to the cell lysis by 1% TritonX-100. The K+ release 
is monitored with atomic emission spectroscopy. [e] > 80 (% killing) as percentage of bacteria 
killing at the highest concentration tested shown before the parentheses 
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Figure 2-11. Effects of Lys N-methylation on antimicrobial activities of gA mutants. a) 
Representative concentration profile of antibacterial activities against S. Pyogenes. The arrow 
marked the change upon Lys N-trimethylation on two series of gA mutants (gA-x with open 
symbol and gA-xM with filled symbol).  b) comparisons of MIC values of gA mutants against S. 
pyogenes before and after Lys N-trimethylation.  
 
Figure 2-12. Cellular toxicities of N-trimethylated Lys containing gA-xM mutants. 
Concentration profiles of a) hemoglobin leakage; b) K+ leakage from hRBCs. The HC 50 and KC 
50 values listed in Table 2-6 were obtained from graphs above.  
70 
 
Table 2-7.  Therapeutic indices comparison of gA-x and gA-xM mutants against the three Gram-
positive strains tested 
Bacterial 
strains 
Therapeutic index 
Folds 
increases Therapeutic index 
Folds 
increases 
gA-1 gA-1M gA-2 gA-2M 
B. subtilis 1.5 7.6 5.0 1.5 4.8 3.2 
S. aureus 3 7.6 2.5 3 9.6 3.2 
S. pyogenes 47 126 2.7 47 308 6.6 
 
therapeutic index was calculated as HC50/ MIC,
40  and the folds of changes upon Lys N-
methylation were calculated as the therapeutic index of gA-xM divided by that of gA-x, in which 
is the peptide number as labeled 
 
To better understand our observation that the less soluble gA mutants (gA-xM) showed 
less potent membrane activities, a series of mechanistic studies in model liposomal systems were 
carried out. Two types of liposomes were used in all characterizations. LUVs, (~100 nm in 
diameter) made of POPC were used as a mimic of hRBCs, while liposomes composed of 
POPC/POPG (1:1) were prepared to represent bacterial membranes. All experiments were 
performed under identical conditions as the studies of the gA-x mutants.  
Firstly, we determined membrane association through titration. Various amounts of 
LUVs were titrated into a solution of peptide (500 nM) and the apparent dissociation constants 
(Kd) of all gA mutants were determined by monitoring Trp fluorescence as described above. 
Surprisingly, all gA-xM mutants exhibited decreased binding affinities with both negatively 
charged (POPC/POPG) and neutral liposomes (POPC only) compared to the gA-x mutants 
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(Figure 2-13, Table 2-8). The decreased membrane association could be responsible for the 
decreased membrane activities. Lys N-trimethylation does not affect the charges carried by the 
peptide in neutral aqueous solution. Therefore, the charge-charge attraction between gA mutants 
and vesicles are not affected. The decreased binding affinity is also contradictory to the increased 
hydrophobicity upon Lys N-trimethylation. We concluded that membrane association of gA 
mutants is not only driven by the electrostatic attractions and hydrophobicity, but also other 
factors. It is likely that hydrogen bonding between lysine sidechains and phospholipid headgroups 
stabilizes the bound form. Replacements of hydrogen with three methyl groups remove the 
hydrogen bond potential from the peptides, consequently, destabilizing the bound form. 
Especially, gA-5M, carrying three N-trimethylated Lys showed no binding to either type of the 
vesicles, which might account for the loss of activities against cells.  
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Figure 2-13.  Comparison of the apparent dissociation constants (Kd) before and after peptides 
Lys N-trimethylation. y-axis represents apparent dissociation constant (Kd) yielded by fitting the 
plot of Trp fluorescence signal (I330/ 350 nm) vs L/P ratio into an exponential function. Two sets of 
peptides were shown as examples in the graph.  
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Table 2-8.  Apparent dissociation constant (Kd in L/P ratio) of gA-x and gA-xM mutants 
Peptide POPC[a] POPC/POPG Peptide[b] POPC POPC/POPG 
gA-1M 9  2 10  3 gA-1 8  4 5  2 
gA-2M 119  36 28  7 gA-2 31  17 13  5 
gA-3M 1365370 711290 gA-3 502132 166 
gA-4M 797  202 168  27 gA-4 532  130 17  5 
gA-5M >2000 >2000 gA-5 >2000 7114 
 
The channel structures of these gA-xM mutants were indirectly probed by the ion 
selective leakage assay (Figure 2-8). We measured the potency of the gA-xM mutants in causing 
K+ and Tb3+ ion leakage from LUVs respectively (Figure 2-14).  gA-5M does not form a channel 
effectively on either vesicle, especially neutral ones. As expected, K+ ions readily diffuse out 
from the interior of vesicles through the channels formed by gA-(1-4)M mutants. Complete K+ 
ions release was achieved at a concentration of 100 nM, while less than 1% of Tb3+ leakage was 
observed at a much higher concentration (500 nM). These results suggested that, gA-xM mutants 
form channels having gA-WT channel structure, which allows only small monovalent ions to 
pass through. In K+ leakage assay, all peptides bound on membrane (L/P ratio ~ 5,000, much 
higher than the determined Kd values). Consistent with the specific toxicity against bacteria, the 
gA-xM mutants shows slightly better channel activities on the negatively charged vesicles 
(POPC/POPG) than on the neutral ones (POPC only) (Figure 2-14a).  Lys N-trimethylation 
changes both the binding affinity and the channel formation potency of the Lys containing 
mutants. However, the binding selectivity actually gets worse with Lys N-trimethylation of gA 
mutants. Binding cannot explain the observed increase therapeutic indices. Further investigation 
in the future needs to be done to address this issue and understand the conformational change of 
gA mutants upon Lys N-trimethylation.  
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Figure 2-14. Ion selectivity of gA-xM mutants. a) gA-xM mutants (95 nM) induced K+ leakage 
from LUVs (500 M, lipids  10 mM HEPES, 150 mM KCl, pH 7.0) detected by potassium ion 
selective electrode. b) gA-xM mutants (500 nM) induced Tb3+ leakage from LUVs (500 M, 
lipids  10 mM TES, 100 mM sodium citrate, 50 mM TbCl3) detected by the luminescence of 
Tb/DPA complex. The negative % in the figure could be experimental error.  
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Figure 2-15. a) HPTS structure, with the pH sensitive 8-hydroxyl group highlighted; b) the 
peptide local environment in EYPC LUVs solutions determined by Trp fluorescence. The y-axis 
represents Trp fluorescence intensity ratio at 330 nm over 350 nm, and the maximum em was 
labeled on top. The premixed samples labeled as “pre“ and samples with peptide added into 
LUVs solution labeled as “add“; c) the kinetic profile of proton diffusion in the premixed 
peptides-lipids system. NaOH solution was added at 100s to generate the transmembrane pH 
gradient; d). the kinetic profile of proton leakage from EYPC LUVs, The exterior bulk solution 
was tuned from pH =7.0 to 7.6 by adding NaOH solution at 100 s before the peptides addition at 
200 s. 
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Another interesting observation was that gA-5M lost channel activity in both model 
systems and cellular experiments, changing from the best antibiotic candidate gA-5 (section 2.2) 
to a nonfunctional molecule upon Lys N-trimethylation. We decided to perform more structure 
activity relationship studies with these two peptides. To evaluate the effect of membrane 
association, we premixed gA-5M and lipids in MeOH/CHCl3 and dried the mixture before 
hydration in liposomes preparation. We hypothesized that peptides would be kinetically trapped 
into the vesicle bound state. If a channel formed on the lipid bilayer, encapsulated K+ ions would 
leak out spontaneously before the measurements. Therefore, an alternative assay was applied to 
monitor the channel activity. HPTS is a membrane impermeable pH sensitive fluorophore (Figure 
2-25a). Its fluorescence intensity strongly depends on ionization state of the 8-hydroxylgroup 
(pKa = 7.3). Upon deprotonation, HPTS fluorescence at 460 nm is dramatically enhanced.41 ,42 ,43  
Anionic lipids like POPG could cause spontaneous proton transport through lipid flip flop.44 ,45  
To monitor the proton diffusion, HPTS (10 M) was encapsulated into the neutral egg yolk 
phosphatidylcholine (EYPC) LUVs. These lipid bilayers are more tightly packed and able to 
effectively maintain a pH gradient (black trace in Figure 2-15c). NaOH was added to the exterior 
buffer to generate a pH gradient. Upon channel formation, protons diffuse out through the 
channel and encapsulated HPTS is deprotonated, and a fluorescence enhancement can be 
observed (Figure1-3b). The local environment of the peptides was determined by monitoring Trp 
fluorescence (Figure 2-15b).46   When gA-5 and gA-5M were added to neutral EYPC vesicles, 
neither of the two peptides bind onto membranes (gA-5M add and gA-5 add bars in Figure 2-15b). 
However, the two peptides are indeed trapped into the membrane bound states in the premixed 
samples (gA-5M pre and gA-5 pre bars in Figure 2-15b). Then the channel activities were 
determined. Consistent with the lack of membrane association, no channel activities were 
observed when gA-5 or gA-5M was added into the EYPC LUVs (red and blue traces in Figure 2-
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15d). However, even if gA-5M was trapped in lipid membranes, it did not cause proton leakage 
(red trace in Figure 2-15c). In sharp contrast, gA-5 causes proton leakage from EYPC LUVs 
when the peptides were trapped in lipid bilayer (blue trace in Figure 2-15c). These data together 
suggested that Lys N-trimethylation not only changed the binding profile but also disturbed the 
structure of the gA-5 mutant. When stuck in lipid membrane as described above, gA-5M may 
adopt a different structure which does not form ion channel. This is supported by secondary 
structure analysis. The CD spectrum of gA-5M showed a different signature from that of gA-WT 
and gA-5 (Figure 2-16).  The structure alteration might also happen in other gA mutants upon Lys 
N-trimethylation. Further analysis is required to understand the detailed structural changes.  
 
 
Figure 2-16. CD spectra of gA-WT, gA-5M and gA-5 in a) DPC or b) SDS micelles at 1: 50 gA: 
lipids ratio. (The spectra shown are the averaged signal of three scans after subtracting the 
background DPC or SDS micelle signal). 
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 2.3.3 Synthesis and characterization of gA mutants with Lys N-dimethylation and D-Lys 
homologs 
 Lys-N-trimethylation not only increases the peptide hydrophobicity, but also removes 
the hydrogen bonding capability. We hypothesize that the hydrogen bonding capability of the Lys 
side chain could be very important for membrane association and channel activity. Instead of 
Lys-N-(Me)3. We then incorporated Lys-N
-(Me)2, which keeps the hydrogen bonding capability 
of Lys side chain, at positions 10, 12, 14. In addition, we synthesized a series of gA mutants with 
different Lys homologs incorporated at positions 10, 12, 14. These homologs have free amine 
groups but different carbon chain length, and varied hydrophobicity (Figure 2-17, Table 2-10). 
Combined together, we would be able to address the contribution of hydrophobicity and hydrogen 
bonds to the antimicrobial activity of gA mutants.  
 
 
Figure 2-17. Structures of  D-Lys homologs incorporated into gA mutants. The names of gA 
mutants with each D-Lys homolog  substitution the D-Leu at positions 10, 12, 14 (highlighted in 
bold, formyl-V-G-A-dL-A-dV-V-dV-W-dL-W-dL-W-dL-W-NHCH2CH2OH) were labeled at the 
bottom . 
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The antimicrobial activities and toxicity of these gA mutants were tested first (Table 2-9).  
No toxicities against hRBCs were observed with any of the gA mutants at the concentrations 
tested (up to 10 M).  Unfortunately, none of the gA mutants showed in Figure 2-17 showed 
higher antimicrobial activities than the gA-5 (Table 2-9, Figure 2-18).  
 
Table 2-9. Antimicrobial activities of gA mutants with Lys homologs  
Peptide 
Minimum Inhibition Concentration (MIC) / M[a] 
B. subtilis S. aureus S. pyogenes 
gA-WT  2.5  2.5  0.16  
gA-5  5  > 10 (80% killing)[c] 0.62  
gA-5M  >80 (80% killing) na(80) [b] > 80 (90% killing) 
gA-5M2  20 na(20)  20 
gA-Orn  10  >10 (50 % killing)  0.625 
gA-Dab  >10 (50 % killing) > 10 (30 % killing) 5 
gA-Dap  > 10 (80% killing)  > 10 (30% killing ) 5  
[a] The minimum inhibition concentration is determined by the standard micro-dilution methods, 
all tests were repeated at least three times to confirm the reproducibility. None of the peptides 
tested was active against the Gram-negative E. coli (data not shown). [b] na (concentration) as no 
noticeable bacteria growth inhibition were observed up the concentration labelled in the 
parentheses. [c] > 80 (% killing) as percentage of bacteria killing at the highest concentration 
tested shown before the parentheses 
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Apparent dissociation constants of these gA mutants listed above were determined by 
monitoring the Trp fluorescence following the same procedure. All gA mutants listed above 
(Figure 2-17) preferentially bind to negatively charged vesicles. However, the trend of membrane 
association does not reflect the antimicrobial activities of these gA mutants (Figure 2-18). The 
gA-Dap tends to aggregate in low L/P ratios, suggested by the blue shifted Trp fluorescence 
spectra. This self-association could affect its channel formation potency and its antibiotic activity. 
However, these preliminary results are not enough to make a conclusion yet. Further investigation 
needs to be done to understand the relationship between gA primary structure and activities.  
 
 
 
Figure 2-18. Apparent dissociation constants of gA mutants with Lys homologs and N-
methylated Lys. The antimicrobial activities presented as MIC values are indicated below. 
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2.3.4 Summary  
In summary, the potential of solubilized gA as antibiotics can be fine tuned by Lys N-
trimethylation. Upon Lys N-trimethylation, antibacterial activities of the gA-(1-3)M mutants 
were mildly affected, while their toxicities against hRBCs are significantly decreased. As a result, 
we gained 2-7 fold increases in therapeutic indices. Studies in model liposomal systems suggested 
that, Lys N-trimethylation affects both the binding affinity between peptides and vesicles, and 
peptides’ structural preference in membranes. For the inactive gA-5M, more detailed analyses 
were performed. Lys N-trimethylation on the gA-5 not only changes the membrane association, 
but also affects the structure of gA-5M. gA-5M did not form channel when the peptide is trapped 
into membranes while gA-5 did. Further investigation of the conformation/structure changes and 
activities needs to be done to fully understand the effect Lys N- trimethylation on these 
antimicrobial peptides. Following our investigation into the gA mutants, we further adjusted the 
properties of cationic gA mutants by incorporating Lys homologs or Lys-N-(Me)2 at positions 10, 
12, and 14. The preliminary results suggest that these modifications fail to make the gA mutants 
better antibiotics than gA-5. More studies of the structure activity relationship should be 
performed to understand the chemical basis of the low antimicrobial activity of these cationic gA 
mutants.  
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2.4 Using boronic acid to target bacterial membranes 
In previous sections, I have introduced our efforts in converting the nonspecific channel 
forming toxin gA into potential bacterium specific antibiotics. It was achieved by targeting the 
anionic charges displayed by bacterial cells through electrostatic attraction with the cationic 
residues incorporated into gA mutants. By tuning the number of cationic residues, hydrogen 
bonding ability and hydrophobicity, we were able to further adjust the properties of these gA 
mutants. Our results suggested that purely relying on the Coulombic interaction is not enough to 
obtain high specific antibiotics.  Novel strategies are needed to specifically target the bacterial 
cell membrane.    
 
2.4.1 Targeting PG headgroup with boronic acid 
As described in section 2.2, the plasma membrane of mammalian cells is largely 
composed of cholesterol and zwitterionic lipids mainly including PC, and SM (Figure 2-19a). In 
contrast, the plasma membranes of both Gram-positive and Gram-negative bacteria consist of 30-
50 % negatively charged lipids mainly including PG and CL, in addition to the zwitterionic PE 
(Figure 2-19b).14 ,15  Bacterium specific membrane toxins reported to date predominantly rely on 
charge-charge attraction as a driving force for the preferential activity against bacterial cells. 
However, such peptides often lose their antimicrobial potency when put into physiologic media, 
presumably because the high salt concentration significantly dampens the Coulombic interactions 
between the cationic peptides and the anionic membranes47 ,48 . Our observed discrimination 
between the channel activity determined in model membranes and the antimicrobial activity 
against bacteria could potentially be attributed to this reason.  Therefore, novel strategies and/or 
synergistic strategies are needed to achieve potent and exquisite recognition of bacterial 
membranes. A close examination of the PG headgroup suggests that besides its global anionic 
charge, the unique 1,2-diol substructure can be considered as a secondary target (Figure 2-19b).   
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Figure 2-19. Structures of major lipid components in a mammallian cell membrane (a), and a 
bacterial plasma membrane (b), and important bacterial cell wall carbohydrates (c). The 1,2-diol 
substructure on the PG headgroup is highlighted with a red square. The carbohydrates in the 
bacterial cell wall lack the 1,2-diol in the syn conformation for boronic acid binding.  
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In supramolecular chemistry, a boronic acid is often used as a synthon to covalently 
target 1,2-diol structures (Figure 2-20a).49 Optimized binding pairs have been used to promote 
drug delivery and to develop tools in glycoprotein detection.50 ,51   The binding affinity between a 
boronic acid and a 1,2-diol varies depending on the structures of each component52 ,53 . In general, 
boronic acids bind tighter to restrained 1,2-syn-diols. We hypothesize that a peptide displaying 
boronic acids will preferentially bind to PG headgroup, and thus able to specifically attack 
bacterial cells (Figure 2-20). Although boronic acids display a modest affinity to glycerol in 
aqueous solutions, we envision that the high density of PG headgroups displayed on the bacterial 
membrane would increase the local concentration dramatically and favor peptide binding,  
 
 
Figure 2-20. Targeting the PG headgroup with boronic acid containing peptides a) binding 
equilibrium between boronic acid and 1,2-diol in aqueous solution; b) boronic ester formation 
between boronic acid containing peptide and PG headgroup ; c) synergized charge-charge 
interaction and boronic ester formation between the PG headgroup and the cationic peptide 
carrying boronic acid 
84 
 
especially when the peptides carry multiple boronic acids. A polyvalent display of boronic acid 
has been proven to promote binding between the carrier protein and sugars.54  In our system, 
potential competition could come from various carbohydrates. However, they are unlikely to be a 
strong trap of boronic acid-containing peptides because monosaccharides only display modest 
affinities to boronic acids while sugar polymers, such as peptidoglycan and teichoic acid do not 
have 1,2-diols in the syn conformation required for boronic acid binding (Figure 2-19c). We 
believe, well organized peptide structures carrying multiple boronic acid moieties would match 
the high density of 1,2-diols and consequently favor bacterial membrane binding.  If these 
boronic acids are introduced into cationic peptides, they will be able to synergize charge-charge 
interaction and boronic ester formation to preferentially target PG over other lipids and 
carbohydrate molecules (Figure 2-20c).  Here I will introduce my project using boronic acid to 
target the 1,2-diol substructure in PG headgroup  and present some preliminary results I obtained 
on this project.  
 
2.4.2 Detection of  boronic acid and 1,2-diol binding 
The binding affinities between boronic acids and representative 1,2-diols were 
determined by a competitive assay. Alizarin Red S (ARS) is a small molecule with a restricted 
1,2-diol  substructure. It has been widely used  to probe boronic acids and 1,2-diol binding.52 ,55  
An excited state proton transfer from the phenol hydroxyl group of ARS (Figure 2-21a) to the 
ketone oxygen results in the fluorescence quenching of free ARS. Upon boronate ester formation 
the quenching is eliminated, therefore, the fluorescence increases (Figure 2-21b). By taking 
advantage of such features, a three-component competitive ARS binding assay has been designed 
to determine the binding affinity of a boronic acid and a variety of diols. In the system, there are 
two competitive equilibria. The first equilibrium, between ARS and boronic acid, phenylboronic 
acid (PBA) to be specific, can be directly measured. The PBA/ARS binding affinity can be 
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determined by fitting the concentration profile into an exponential function (Figure 2-21c). The 
addition of other 1,2-diol molecules sets up the second equilibrium and perturbs the ARS/PBA 
equilibrium. To be more specific, the additional 1,2-diol forms a complex with PBA and then 
release ARS from the original ARS/PBA complex; consequently the fluorescence of the solution 
decreases as more and more competitive 1,2-diols are added to the solution (Figure 2-22).  Based 
on the fluorescence intensity at 582 nm, the inhibitory concentration can be obtained, which 
reflects the binding affinity of 1,2-diol of interests and PBA. The smaller the value the tighter 
they bind.   
 
Figure 2-21.  Competitive binding assay for determination of boronic acid and 1,2-diol complex 
formation. a) The two competitive equilibria in the ARS binding assay; b) the florescence spectra 
of ARS with various amounts of PBA in aqueous solution, (10 M ARS, 0.1 M PBS, pH 7.0, ex 
= 468 nm), the fluorescence intensity at 582 nm increases as the amount of PBA increases; c ) the 
concentration profile  I582 nm and PBA concentration fitted into an exponential function. 
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Using fructose, glucose and glycerol as model diol molecules and PBA as the model 
boronic acid partner, we determined the respective dissociation constants with this ARS binding 
assay. Consistent with earlier reports, boronic acids bind better with constrained 1,2-syn-diols. 
The fructose inhibits the ARS-PBA fluorescence complex formation at a concentration of 14 mM, 
which is 32 times smaller than that of glucose. The difference in affinity is due to the favored 1,2-
syn-diol in the most stable fructose conformation. No obvious PBA binding was observed with up 
to 1.5 M of glycerol added to the system. The loose binding between glycerol and boronic acid 
could be due to the rotation freedom. High entropy cost is expected when adjacent hydroxyl 
groups in glycerol are locked into the five-membered ring of boronic ester. Enhanced binding was 
indeed observed when 1,2- diol is displayed by the terminal in organized PG containing vesicles. 
It could be attributed to the increased local concentration (polyvalent display of diol structures).  
 
 
Figure 2-22.  Inhibition of the ARS-PBA complex formation by different diols. a) Plots of the 
normalized fluorescence intensity at 582 nm against substance concentrations, in which total 
lipids concentration was used for PC/PG SUVs; b) the structure of substance tested.  
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On the other hand, a polyvalent display of boronic acids on a peptide also showed 
enhanced binding with diols. The incorporation of the PBA moiety was achieved by using the 
amino acid Fmoc- protected boronophenylalanine (Fmoc-Bpa(pin)-OH, Figure 2-23). The amino 
acid was synthesized by Dr. Qin in our group (Figure 2-23, top panel). Specifically, the synthesis 
starts from Boc- protected iodophenylalanine. The Boc-Bpa(pin)-OH was obtained through 
PdCl2(dppf) catalyzed Miyaura borylation reaction with K2CO3 as the base in DMF. Then the 
Boc- group was cleaved by neat HCl in acetonitrile to achieve the unprotected H-Bpa(pin)-OH. 
The Fmoc-protection was carried out in DCM with Fmoc-Cl. The overall yield for the Fmoc- 
protected amino acids was 62% over three steps. Then the amino acid can be directly 
used in peptide synthesis. It is compatible with Fmoc/HBTU chemistry.56  
The polyvalent display of boronic acids was tested with the peptide LP3B (lipid 
binding peptide with 3 PBA moieties, CBKBKBKWG, in which B stands for 
boronophenylalanine(Bpa)). The peptide sequence was designed according to the 
following reasons. 1) Tryptophan was chosen as a probe for concentration calibration or 
peptide binding with the membrane. 2) The terminal cysteine will conjugate with long 
wavelength fluorophore in future experiments, which could be potentially useful in 
bacterial imaging and flow cytometry analysis. 3) The cationic lysine residues were 
chosen to have Coulombic attraction with the anionic charges, resulting in potential 
synergistic effects.  The peptide was synthesized by standard SPPS applying the 
Fmoc/HBTU chemistry. Standard TFA cleavage after the peptide synthesis failed to 
remove pinacol(pin) protecting groups completely (Figure 2-24a). The product is a 
mixture of four peptides carrying zero to three pinacol protecting groups. Therefore, we 
applied a boronic ester exchange step with a high concentration of free PBA solution in 
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COOHBocHN
B2pin2, PdCl2(dppf)
K2CO3, DMF, 75 oC
           94%
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COOHBocHN
dry HCl, CH3CN
4oC, 0.5 h, 90%
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COOH+H3N
Cl-
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         84%
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COOHFmocHN
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peptide
B(OH)2 B(OH)2
(HO)2B
peptide
1. 1.6 M phenylboronic acid in DMF
2. TFA peptide cleavage OH
Wang resin
Fmoc-Bpa-OH
DMF (1.6 M, overnight) before the TFA treatment to obtain the fully deprotected peptide 
in high purity and high yield (Figure 2-24b)56 ,57 .  
 
 
 
 
 
 
  
Figure 2-23. Synthesis of boronopeptides using standard solid phase peptide synthesis with 
Fmoc/HBTU chemistry. Through a three step procedure, we prepared the pinacol protected Bpa, 
also abbreviated as B in peptide sequence) in Gram quantities (prepared by Dr. Qin). Then the 
amino acid was incorporated into the peptide as a building block. 
 
Interaction between the LP3B and the 1,2-diol was also determined by the ARS 
binding assay. Firstly, the fluorescence probe ARS was used as a model 1,2-diol. 
Compared to the PBA, the peptide gives an enhanced affinity for ARS binding (Figure 2-
25) . We envision that even tighter binding can be achieved by matching the polyvalency 
of boronic acids on a peptide and the high density PG terminal diols on a membrane. 
Unfortunately, the peptide LP3B suffers from poor water solubility, which prohibits its 
evaluation against lipid vesicles in aqueous solution (peptide binding with ARS was 
evaluated in a 1:1 mixture of methanol/ water (v/v).   
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Figure 2-24. Illustration of LP3B peptide synthesis. a) analytical HPLC traces of LP3B peptide 
cleaved off the wang resin with reagent K; b) analytical HPLC trace of LP3B peptide cleaved off 
the resin with reagent K after boronic ester exchange reaction. Identity of each peak is determined 
by MS (ESI+-TOF). Larger retention time in the bottom trace is because a slower gradient was 
used in the confirmation of the final product.  
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Figure 2-25.  a) comparison of monomeric and polymomeric PBA binding with ARS. b) Effect 
of MeOH addition on PBA-ARS complex formation (0.1 M PBS, pH 7.0 only or a mixture of 0.1 
M PBS/MeOH (v/v =1/1) pH 7.0) and the I 582 nm was plotted against the PBA concentration and 
fitted into an exponential function. 
Collectively, these preliminary results suggest that the organized and high density 
display of the 1,2- diol on the PG containing membranes and  polyvalent boronic acids 
both enhance the formation of the PBA-diol complex. Due to the poor water solubility of 
the LP3B peptide, I was not able to test the binding between the polyvalent boronic acids 
and polyvalent 1,2-diols nor the peptides’ ability in differentiating PC only SUVs from 
PG containing SUVs . We suspect that the poor water solubility originates from the lack 
of net charge as the cationic Lys and anionic Bpa may form ion pairs with each other. To 
circumvent this problem, we will put in extra positive charges into the peptides in the 
future.   
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Figure 2-26. Structures and electronic properties of PBA and Tyr calculated in Spartan 
using the PM model as neutral molecules.  
 
We will further elucidate the potential of boronopeptides in targeting bacterial 
cells by incorporating Bpa residues into gA. Similar to the D-Lys residues (Section 2.2), 
the PBA moiety should be accommodated toward the C-terminus of gA, which is 
expected to be better accommodated without disturbing the channel structure. The 
electronic properties of the PBA moiety were calculated in Spartan (Figure 2-26).  These 
properties are very similar to tryrosine, which made the most active channel (Figure 1-11). 
Therefore, we would expect a mutant with relatively high channel potency when Bpa is used to 
replace the Trp residues. Given its low hemolytic activity, the triple D-Lys mutant gA-5 (Table 2-
2) will be used as a starting point to incorporate a varied number of Bpa residues. If our 
hypothesis is correct, there will be an borono-Lys-gA with optimized number of Bpa and Lys 
showing good water solubility, lower MIC values against bacteria while showing negaligible 
hemolytic activity.  
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2.4.3 Summary  
In summary, our approach in targeting PG containing bacterial membrane jumps out of 
the canonical wisdom of exploiting the negative charge of bacterial membranes. Instead of the 
charge-charge attraction, we seek to develop covalent chemistry to target the PG head group.  
Success of this research will provide a different view in designing novel antibiotics and even 
bacterial imaging agents.  
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2.5 Materials and methods 
I. General methods 
Wang resin, all Fmoc-protected amino acids and Boc-protected amino acid were 
purchased from either Advanced Chemtech (Louisville, KL) or Chem Impex Int. Inc (Wood Dale, 
IL). Unprotected valine and other chemicals were obtained from Sigma-Aldrich unless otherwise 
indicated. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt (POPG) were purchased from Avanti Polar 
Lipids (Alabaster, AL). Peptide synthesis was carried out on a Tribute peptide synthesizer 
(Protein Technologies, Tucson, AZ). PBS buffer, DMEM/High glucose media, Pen/Strep were 
purchased from Thermo Scientific (Amarillo, TX). Fatty acid-free bovine serum albumin (BSA), 
0.25% Trypsin-EDTA solution, MTT cell proliferation Assay Kit were purchased from 
Invitrogen (Carlsbad, CA).1HNMR data were collected on a Varian Gemini 500 MHz NMR 
spectrometer. LC/MS (ESI+) data were generated by the Boston College Mass-Spectrometry 
facility. The protein concentration of all samples used in this study was determined by measuring 
their absorbance at 280 nm on a Nanodrop 2000c UV/Vis spectrometer. The liposomes were 
prepared by using Liposofast Mini Extrusion system (Avanti Polar Lipids, Alabaster, AL). All 
three Gram-positive negative bacteria (B. subtilis (ATCC 663), S. aureus (ATCC 6538) and S. 
pyogenes (ATCC 19615)) used in antibiotic activity tests were purchased from Microbiologics 
(Cloud, MN) as lyophilized cell pellet. E. coli (BL21) was a gift from the lab of Professor Mary. 
F. Roberts at Boston College.  
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II. Peptide synthesis and characterization 
1. Synthesis of formyl-L-valine 
Acetic anhydride (4 mL, 0.04 mol) was added dropwise to a solution of L-Valine (1 g, 
8.35 mmol) in formic acid (12 mL, 0.32 mol) while stirring on ice. The mixture was then warmed 
up to RT and kept stirring for 24 hours before the solvent was removed by rotary evaporation 
under high vacuum.  The formyl-valine was recrystallized from ethyl acetate and the desired 
product was obtained as a white solid. Yield: 0.78 g (64%) 1HNMR (500 MHz, [d5] Acetone, 
25 °C, TMS ):  = 8.22 (s, 1H), 7.41(b, 1H), 4.50 (m, 1H), 2.22 (m, 1H), 0.98(m, 6H).  
 
2. Synthesis of Fmoc-D-Lys-N-(Me)2-OH58  
Fmoc-N-Boc-D-Lys-OH (1.4 g, 3 mmol) was dissolved in formic acid (20 mL) and 
stirred at room temperature for 3 hours. The solvent was then removed by rotary evaporation. 
Trituration in diethyl ether yielded Fmoc-D-Lys-OH formate salt as a white solid (1.2 g, 98% 
yield, confirmed by LC/MS in high purity, calculated (M)+: 368.43. found (M+H)+: 369.25). To a 
stirred solution of the salt (600 mg, 1.4 mmol) in MeOH, 37% of aqueous formaldehyde (607 L, 
8.1 mmol) was added. After stirring for 20 min, the reaction mixture was cooled to 0 oC in an ice 
bath.  NaCNBH3 (180 mg, 2.8 mmol) dissolved in MeOH (2 mL) was added dropwise to the 
reaction. After warming to room temperature, the mixture was then stirred for 2 hours. The 
solvent was removed by rotary evaporation and the product was redissolved in acetone. Insoluble 
solid was removed by filtration. The filtrate was dried in vacuo to yield the product as a white 
solid (526 mg, 95% yield). The product is confirmed by LC/MS in high purity (calculated M+: 
396.2. Found (M+H)+: 370.15) and 1H-NMR(DMSO-d6): d 7.26–7.92(8H, m), 7.1(1H, d), 4.3(3H, 
m), 3.75–3.77(1H, m), 2.27–2.36(2H, t), 2.2(6H, s), 1.22–1.37(4H, m), 1.49–1.69(2H, m) 
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3. Synthesis of gA mutants 
Peptides, except the Lys N-trimethylated gA mutants, were synthesized directly on 
Fmoc-Trp-Wang resin (64 mg, 0.79 mmol/g, 0.05 mmol) using standard Fmoc/HBTU chemistry. 
Five equivalents of each amino acid were used for the coupling reaction.  The peptides were 
cleaved from the resin by treating the resin with ethanolamine (40% (v/v) in degassed DMF, 55oC, 
5 hours).22  Then the resin was filtered through a medium fritted plastic funnel and rinsed three 
times with DCM and methanol to release the peptide efficiently into solvent. The filtrate 
containing peptide was dried by rotary evaporation to a minimal volume. Then six to seven times 
in volume of water was added to precipitate the peptide and the precipitation was separated out by 
centrifugation (14,000 rpm, 1 hour). The pellet was dried on lyophilizer to yield the side-chain 
protected peptide.  The Boc protecting group on d-Lys was removed by treating the pellet with a 
mixture of 95% TFA, 2.5% TIS and 2.5% H2O at RT for 2 hours. The Pbf protecting group on 
arginine was removed by reagent K (80% TFA, 5% H2O, 2.5% EDT, 5% Thioanisole and 7.5% 
Phenol, 2 hours at RT). Once the reaction is finished, cold diethyl ether was added to give the 
crude peptide as white precipitate.  The precipitate was again pelleted by centrifugation. The 
crude material was purified by RP-HPLC (Waters Prep LC, Jupiter 10 m C4 300A Column). 
The identity and purity of each peptide was confirmed by analytical RP-HPLC-MS (ESI+) 
(Waters e2695, Phenomenex, Jupiter 5m C4 300R). All peptides were confirmed to have purity 
of 95% or higher.  
The Lys N-trimethylated gA mutants (gA-xM) were synthesized from the Lys 
containing mutants (gA-x). gA-x mutants were dissolved in acetonitrile. To the stirred solution, 
methyl iodide (20 eq) and DIPEA (30 eq) were added. The mixture was stirred at 80 °C for 24 
hours in a pressure vessel. After cooling down, solvents and excess methyl iodide were removed 
by rotary evaporation. The residues were dissolved in acetonitrile/water mixture and peptides 
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were isolated by RP-HPLC. All peptides were confirmed by analytical RP-HPLC-MS (ESI+) 
(Waters e2695, Phenomenex, Jupiter 5m C4 300R) to have purity of 95% or higher. The MS 
results were listed in Table 2-10.  
 
Table 2-10. LC-MS results of gA mutants 
Peptides m/z  calculated m/z  found 
gA-1 1899[M]+ 949.8/950.2 [M+2H]2+ 
gA-2 1899 [M]+ 1900 [M+H]+, 948.8/950.2[M+2H]2+ 
gA-3 1913 [M]+ 957.3/957.8 [M+2H]2+ 
gA-4 1913 [M]+ 957.8/958.3 [M+2H]2+ 
gA-5 1927 [M]+ 964.7 [M+2H]2+ 
gA-6 2012[M]+ 671.4/671.8/672.1[M+3H]3+,1006.9/1007.4/1007.9 [M+2H]2+ 
gA-1M 1941[M]+ 1942.0 [M+H]+, 971.2/971.8/982.3 [M+2H]2+ 
gA-2M 1941 [M]+ 1942.0 [M+H]+, 971.2/971.8/982.3 [M+2H]2+ 
gA-3M 1997 [M]+ 999.9/1000.4/1000.9 [M+2H]2+ 
gA-4M 1997 [M]+ 999.9/1000.4/1000.9 [M+2H]2+ 
gA-5M 2053 [M]+ 685.1/685.4/685.7 [M+3H]3+ 
gA-5M2 2011[M]+ 670.7/671.0/671.3[M+3H]3+, 1006.2 [M+2H]2+ 
gA-Orn 1885[M]+ 630.7/631.0 [M+3H]3+ , 944.5 [M+2H]2+ 
gA-Dab 1444[M]+ 615.7/616.1 [M+3H]3+ , 922.3/922.8/923.3 [M+2H]2+ , 1845.0  
gA-Dap 1402[M]+ 467.3/467.7/468.1[M+3H]3+ 
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4. Synthesis of boronopeptide 
Boronopeptide (LP3B) was synthesized using the same SPPS procedures described above.  
The PBA moiety was incorporated by the Fmoc-boronophenylalanine-OH (Fmoc-Bpa-OH). The 
Fmoc-Bpa-OH was synthesized with a three step reaction developed by Dr. Qin (Figure 2-23). 
After peptide elongation, the pinacol protecting groups were removed by a boronate ester 
exchange reaction on resin. Specifically, the resin loaded with LP3B peptide was incubated in 1.6 
M of PBA in DMF overnight. Next, the resin was washed with DMF, MeOH and DCM three 
times respectively.  Finally, the peptide was cleaved off the resin with reagent K (80% TFA, 5% 
H2O, 2.5% EDT, 5% Thioanisole and 7.5% Phenol, 2 hours at RT). Once the reaction is finished, 
cold diethyl ether was added to give the crude peptide as white precipitate.  The precipitate was 
separated by centrifugation. Crude material was purified by RP-HPLC (Waters Prep LC, Jupiter 
10 m C18 300A Column). The identity and purity of each peptide was confirmed by analytical 
RP-HPLC-MS (ESI+) (Waters e2695, Phenomenex, Jupiter 5m C18 300R, Figure 2-24b), 
calculated [M]+ 1323, identified [M+3H] 3+ 442.  
 
III. Peptide Solubility test 
Peptide solubility in 10 mM HEPES buffer with 1% DMSO was measured by monitoring 
Trp absorbance at 280 nm.  A concentrated (6.0 – 8.0 mM) peptide stock solution in DMSO was 
diluted 100 times (5 L of the stock into 500 l of 10 mM HEPES buffer, pH 7.0). The mixture 
was sonicated for 30 min and then subject to centrifugation (14,000 rpm, 10 min) to remove 
possible precipitate. The supernatant (400 L) was transferred to a quartz cuvette (1 cm path 
length) and the peptide concentration was calculated according to Beer’s law. Representative 
UV/Vis spectra of the supernatant are shown in Figure 2-5. 
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IV. Model membrane studies 
 Buffer A: 10 mM HEPES, 150 mM NaCl, pH 7.0 
 Buffer B: 10 mM TES, 150 mM sodium citrate, pH 7.0 
 
1. Liposome preparation 
 
A chloroform solution containing 76 mg of POPC (for POPC LUVs preparation) or a 
chloroform/methanol (1/1)  containing 38 mg of POPC and 38.5 mg POPG sodium salt (for 
POPC/POPG LUVs preparation, POPC︰POPG=1︰1) was dried under reduced pressure to 
receive a thin film which was then hydrated with 2 mL aqueous buffer: (1) 10 mM HEPES, 150 
mM KCl, pH 7.0 for K+ leakage assay; (2) 10 mM TES, 100 mM sodium citrate, 50 mM TbCl3, 
pH 7.0 for Tb3+ leakage assay; (3) 10 mM HEPES, 150 mM NaCl, pH 7.0 for peptide binding 
assay. After 20 cycles of freezing and thawing, the liposome suspension was extruded 21 times 
through a 100 nm polycarbonate membrane (Liposofast Mini Extrusion system, Avanti Polar 
Lipids; Whatman Nuclepore Track-Etch Membrane) at RT. Free K+ or Tb3+ were removed by gel 
filtration (ÄKTA FPLC with HiPrepTM 16/60 Sephacryl TM-S-500HR column) using Buffer A 
for (1) and (3) or Buffer B for (2) as the eluent.  The lipid concentration was determined by 
Stewart assay[6] and the size of liposome was confirmed by Dynamic Light Scattering (DLS, 
DynaPro nanostar, Wyatt, Santa Barbara, CA). The instrument setup used the standard PBS 
parameters: refractive index @589 nm & 20○C is 1.333, viscosity is 1.019 cp, Cauchy coefficient 
is 3119 nm2. Data were acquired in auto-attenuation mode, and processed with DYNAMIC 
V6TM software. The diameters of all liposomes were found to fall into the narrow range of 
100~150 nm with a polydispersity lower than 30%.  After gel filtration the polydispersity of all 
liposome preparation is below 20%. The total lipids concentration in POPC/POPG LUVs was 
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calculated by doubling the measured POPC concentration, as the Stewart assay does not report 
the amount of POPG.  
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Figure 2-27. An representative bar graph of liposome size distribution determined by dynamic 
light scattering (POPC/POPG 1:1 LUVs). 
 
2. K+ leakage assay 
 
The K+ leakage from liposomes was determined by a potassium ion selective electrode 
(K-ISE) (Cole-Parmer, Vernon Hills, Il). The electrode was calibrated each day before 
experiments. A liposome solution in Buffer A (2 mL, 500 μM POPC or POPC/POPG  10 mM 
HEPES, 150 mM KCl, pH 7.0) was stirred at constant speed and peptide at various concentration 
(1 μL in DMSO) was added accumulatively. Three minutes after each peptide addition, the K+ 
concentration was measured and reported as potential. At the end, WT gA stock (1 μL, 1 mM) 
was added to induce 100% K+ leakage.  The potential reported by the K-ISE was plotted against 
peptide concentration after the background signal (caused by DMSO addition) was subtracted and 
normalized to 0 – 100%.  
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3. Peptide binding onto membranes 
Peptide partitioning into lipid bilayers was monitored by fluorescence enhancement of 
tryptophan upon binding to hydrophobic liposomes. gA mutants (500 nM ) were mixed with 
various amounts of liposome in Buffer A (POPC  10 mM HEPES, 150 mM NaCl, pH 7.0 or 
POPC/POPG  10 mM HEPES, 150 mM NaCl, pH 7.0). The mixture was agitated gently for 30 
min before the tryptophan fluorescence spectra were scanned between 320 nm and 360 nm on a 
SpectraMax M5 (Molecular Devices, Sunnyvale, CA). For each peptide, the ratio of fluorescence 
intensity at 330 nm and 350 nm (I330nm/I350nm) was calculated and plotted against the Lipid/Peptide 
ratio (L/P ratio). The curve was fitted into an exponential function to give an apparent binding 
constant. Figure 2-28 shows some representative binding curves acquired.  
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Figure 2-28. Representative binding curves of gA peptides, fitted with exponential function. 
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4. Tb3+ leakage assay 
 
The leakage of Tb3+ from liposome was monitored by the fluorescence of Tb/DPA 
complex[7]. To a mixture of vesicles (500 M, POPC or POPC/POPG  10 mM TES, 100 mM 
sodium citrate, 50 mM TbCl3 ) and DPA (50 M) in Buffer B, peptide was added (0.5 M, 2 L 
of 250 M stock in DMSO; 5M, 5 L of 1 mM stock in DMSO). The peptide liposome mixture 
was incubated at RT for 30 min before the fluorescence intensity of Tb/DPA complex 
(ex=270nm, em=490 nm) was recorded (Ic) in a quartz cuvette on a MicroMax 384 fluorescence 
spectrometer (Jobin Yvon, Horiba Scientific).  Complete Tb3+ leakage was assessed by Triton X-
100 lysis of liposomes (If). A sample with pure DMSO added was used as a blank (I0) and the 
fraction of Tb3+ leakage was calculated as fraction = (Ic-I0)/(If-I0) . 
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Figure 2-29. Representative luminescence spectra of the Tb3+/DPA complex leakage assay upon 
peptide (500 nM) addition to POPC/POPG LUVs (there is no noticeable difference in the spectra 
of gA-WT, gA-5 and DMSO addition). 
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5. Peptide secondary structure by Circular Dichroism  (CD) spectrum  
gA analogues (0.2 mol) dissolved in DMSO were mixed with Fos-phosphatidylcholine-
C12 (DPC, 10 mol) or sodium dodecyl sulfate (SDS, 10 mol) in methanol (L/P ratio 50). Then 
the mixture was dried by rotary evaporation and lyophilized overnight to remove all possible 
solvent. Next, dry Gramicidin/DPC or SDS films were resuspended in N2-flushed H2O (2 mL) 
before the incubation (55oC, 15 min) and   ultrasonication (RT, 1 min) cycles (three times) were 
performed[8]. The micelles containing peptides were centrifuged at 12,500 rpm for 5 min to 
remove possible aggregation and other residues generated in ultrasonication. The supernatant was 
transferred into a quartz cuvette and CD spectra were recorded (RT, 1 cm path length, scan 200-
275 nm, integration time 3s) on AVIV Model 420 Circular Dichroism Spectrometer (Biomedical 
Inc, Lakewood, NJ).  
 
V. Antimicrobial activity 
1. Minimal Inhibitory Concentration measurements  
 
Minimal Inhibitory Concentrations (MICs) were measured against Gram-negative E. coli      
(BL21) and Gram-positive B. subtilis (ATCC 663), S. aureus (ATCC 6538), S. pyogenes 
(ATCC19615) using the broth microdilution method.[2]  Specifically, bacteria from a single 
colony were grown overnight in LB broth at 37oC with agitation.  An aliquot was taken and 
diluted (1: 50 for E. coli, 1:20 for B. subtilis, 1:200 for S. aureus, 1: 10 for S. pyogenes) in fresh  
broth and cultured for another  3 hours until the cells reach mid-logarithmic phase (OD590  0.6). 
The cells were diluted to a concentration of  5  105 Colony Forming Units/ml (CFU/ml) and the 
bacteria suspension (200 L) was added to each well of a sterile 96-well plate. Serial diluted (2-
fold) peptides in DMSO (2 L) were added in triplicates. The plates were shaken for 30 seconds 
to mix the peptide solution well with the broth, and then incubated at 37oC overnight before the 
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optical density at 590 nm was monitored using a microtiter plate reader (SpectraMax M5, 
Molecular Devices, Sunnyvale, CA).  The viability of the bacterial was normalized as % survival 
= (ODpep,bac- ODbroth only)/ (ODDMSO, bac-ODbroth only) 100%. The effect of 1% DMSO is negligible 
as the bacterial cell density with DMSO addition is comparable with that of bacterial suspension 
in LB Broth. The MIC was recorded as the peptide concentration required for complete inhibition 
of cell growth (no change in absorbance).  Representative curves plotting the cell viability against 
the peptide concentration are shown in Figure 2-30.  
 
 
 
Figure 2-30. Antibiotic activity profiles for (a) gA-WT and (b) gA-5 against bacteria strains 
tested  
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VI. Toxicity against mammalian cells 
1. Hemoglobin release from hRBCs 
 
Fresh hRBCs were centrifuged at 3500 rpm and washed with PBS buffer until the 
supernatant was clear. The hRBCs were then resuspended and diluted to a final concentration of 1% 
(v/v) in PBS and used immediately.  15 L of serial dilution (2-fold) of peptides in DMSO or 
DMSO alone as negative control was added to 1.5 mL of hRBCs in PBS. The resulting mixture 
was gently shaken to mix well and incubated at 37oC for 1 h, followed by centrifugation at 3500 
rpm for 10 min using tabletop centrifuge.  Aliquot (50 L) of supernatant (in triplicates) was 
transferred into a sterile 96-well plate containing 50 L of H2O in each well. Release of 
hemoglobin was monitored at 415 nm using a microtiter plate reader. Percentage hemolysis was 
calculated using percentage hemolysis = 100 • (A415, peptide- A415, DMSO)/ (A415, complete hemolysis- A415, 
DMSO), where complete hemolysis is achieved by mixing hRBCs with 1% TritonX-100.  The 
peptide concentration required to cause 50% hemoglobin leakage was read out from the graph 
and listed in Table 2 as HC50.  
 
2. K+ leakage from hRBCs 
 
The rest of supernatant (1.2 mL) from each sample prepared as described in the 
hemoglobin leakage assay was transferred into a new sterile eppendorf tube and subject to the K+ 
concentration measurement using a flame-atomic emission spectrometer (em= 766.5 nm) (Perkin 
Elmer Atomic absorption Spectrometer 3100, acetylene/air flame ). Three readings were taken for 
each sample and averaged as final results.  The fraction of K+ leakage from hRBCs was 
calculated as percentage K+ leaked = 100 • (I776.5, peptide- I776.5, DMSO)/ (I776.5, complete lysis- I776.5, DMSO). 
The peptide concentration required to cause 50% K+ leakage was read out from the graph and 
listed in Table 2 as KC50. 
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3. Toxicity against representative human cell lines 
Toxicity of gA-WT and gA-5 were tested against two human cancer cell lines, HeLa and 
MCF-7 (gifts from professor Eranthie Weerapana at Boston College) by using the MTT assay as 
described in the protocol provided by Invitrogen. [5] Hela cells (in DMEM high glucose media 
with 10% FBS, 1% Pen/Strep, 37 oC, 5% CO2) and MCF-7 cells (in RPMI media with 10% FBS 
and 1% Pen/Strep, 37 oC, 5% CO2) were grown to about 80% confluence before being removed 
from the surface of 20 cm petri-dish with 25% trypsin with EDTA (3-5 minutes, 37 oC, 5% CO2). 
Cells were pelleted (3,500 rpm, 5 minutes at 4 °C), and plated at 15,000 cells per well (100 L 
per well) in a 96-well plate, then incubated for 48 h before peptide addition.  
gA stock solutions in DMSO with varied concentration were prepared so that for each 
peptide concentration the total volume of DMSO addition was kept constant at 1 μL (1% total 
volume).  For each concentration, samples were set up as four replicates.  Control wells were 
loaded with 1 μL of DMSO.  After overnight incubation, cells were washed once with PBS before 
being incubated for 4 h with 110 μL of 12 mM 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dissolved in RPMI midia.  The MTT assay was quenched 
with 100 μL of 10% SDS in 0.01 M HCl and allowed to incubate overnight before absorbance at 
570 nm was recorded.  Wells were averaged and standard deviations determined for each peptide 
concentration.  Data was normalized to the DMSO control to give % cell survival (Figure2- 3). 
 
VII. ARS competitive binding assay: 
First, the association constant for the ARS-PBA complex was determined. This was 
accomplished by mixing the following two solutions in various ratios: solution A, 10 M ARS in 
0.1 M PBS buffer pH 7.0; solution B, 10 M ARS and 2 mM PBA in 0.1 M PBS buffer pH 7.0. 
In the mixture, the ARS concentration is kept constant while the amount of PBA increases as the 
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amount of solution B increases. Each mixture was agitated gently for 10 minutes before the 
fluorescence spectrum was recorded ( ex = 468 nm) in a quartz cuvette on a MicroMax 384 
fluorescence spectrometer (Jobin Yvon, Horiba Scientifics).  The fluorescence intensity at 582 
nm was then plotted against the PBA concentrations.  The data was then fitted into an exponential 
function to obtain the apparent binding constant (Kd).  
To determine the binding affinities of the PBA and other 1,2-diol molecules, the 
competitive binding assay were applied. A third solution was prepared. For small molecules like 
sugars and glycerol, solution C contains 10 M ARS and 2 mM PBA together with 1M of sugar 
or 1.5 M glycerol respectively in 0.1 M PBS buffer pH 7.0.  
To test the PBA binding with 1,2-diol presented on the PG containing membrane, PC/PG 
(1:1) SUVs was used. 97 mg of POPG and 95 mg of POPC was dissolved in MeOH/CHCl3 
mixture, and the solution was dried under high vacuum to form a thin layer. The lipids were 
hydrated with 5 mL of solution B by ultrasonication until the solution becomes transparent (about 
20 min). Small unilamellar vesicles (SUVs) formed during the process were filtered through 0.2 
m syringe filters to remove possible aggregates and small amounts of metal tips from the 
ultrasonication probe. A solution D containing 20 mM lipids (PC/PG 1:1), 10 M ARS and 2 mM 
PBA in 0.1 M PBS buffer pH 7.0 was prepared. Solution B and solution C (for PBA-sugar 
binding) or solution B and solution D (for PBA-PG vesicles) were mixed in various ratios to 
obtain mixtures with constant amount of ARS, PBA but various amount of 1,2-diol molecules of 
interests. The mixtures were agitated at room temperature before the fluorescence spectra were 
recorded as described above.  
The binding between the LP3B and 1,2-diols were determined with the same method. 
Due to the poor solubility of LP3B, a mixture of MeOH and 0.1 M PBS (1/1) pH 7.0 was used as 
solvent. The addition of MeOH does not affect the ARS-PBA binding, despite an increase in the 
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absolute fluorescence intensity of the mixture (Figure 2- 27). A solution of 0.5 mM peptide and 
10 M ARS was mixed with 10 M ARS in various ratios, resulting in a series of solution with 
constant amount of ARS and various amount of peptide.  Then the fluorescence spectra of the 
mixture were recorded and the data collected was analyzed as described above.  
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